

THE UNIVERSITY OF BRITISH COLUMBIA
Curriculum Vitae for Faculty Members

Date: 1 May 2014

1. **SURNAME:** LAHER **FIRST NAME:** Ismail
2. **DEPARTMENT/SCHOOL:** Pharmacology and Therapeutics
3. **FACULTY:** Medicine
4. **PRESENT RANK:** Professor **SINCE:** 2005
5. **POST-SECONDARY EDUCATION**

University or Institution	Degree	Subject Area	Dates
University of London	B.Sc. (Hons)	Pharmacology	1974-1978
University of British Columbia	M.Sc.	Pharmacology	1978-1980
Memorial University of Newfoundland	Ph.D.	Pharmacology	1980-1983

Special Professional Qualifications

Certificate on Teaching and Learning in Higher Education. The University of British Columbia. 2006

6. **EMPLOYMENT RECORD**

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
University of Vermont	Postdoctoral Fellow	1983-1986
University of Vermont	Research Associate	1986-1986
University of Vermont	Research Assistant Professor	1986-1991
University of Cape Town	Principal Scientific Officer, MRC	1991-1991
University of Vermont	Visiting Associate Professor	1991-1992
University of Vermont	Research Assistant Professor	1992-1995
University of Vermont	Visiting Assistant Professor	1995-1998
University of Vermont	Visiting Associate Professor	1998-

(b) *At UBC*

Rank or Title	Dates
Assistant Professor	1995-2000
Visiting Associate Professor (University of Vermont, Vermont)	1998-2006
Associate Professor	2000-2005
Professor	2005-
Visiting Professor (University of Angers, France)	2006-2007
Visiting Adjunct Professor (University of Vermont)	2007-
Visiting Adjunct Professor (University of Isfahan)	2009-

(c) *Date of granting of tenure at U.B.C.: 2000*

7. **LEAVES OF ABSENCE**

University, Company or Organization at which Leave was taken	Type of Leave	Dates

8. **TEACHING**

(a) *Areas of special interest and accomplishments*

TEACHING EXPERIENCE

- 1976-1977: Research Assistant, Pharmacology Lab Assistant; Faculty of Pharmaceutical Sciences, University of British Columbia.
- 1980-1983: Lectures in Autonomic Pharmacology to 1st and 2nd Year Medical Students, Memorial University of Newfoundland.
- 1980-1983: Laboratory demonstrator in medical student and graduate student pharmacology courses, Memorial University of Newfoundland.
- 1985-1990: Lectures in Autonomic Pharmacology to Undergraduate Students, University of Vermont.
- 1992-1995: Lectures in Pharmacology to Graduate and Undergraduate Students, University of Vermont.
- 1998- Lectures in Cardiovascular Pathophysiology (Medicine 570), Department of Pathology and Laboratory Medicine, University of British Columbia.
- 1997- Tutor in Problem Based Learning for Medical and Dental Students, The University of British Columbia.
- 1999-2000 Lectures to Second Year Medical and Dental Students (Growth and Reproduction Block; Endocrinology Block).
- 1998-2000 Lectures to Second Year Medical and Dental Students (Musculoskeletal System Block).

- 2005- Lectures to First Year Medical and Dental Students (Principles of Human Biology Block)
- 2005- Tutor, Autonomic Pharmacology Workshop (~30 Year 1 Medical Students)

(b) *Courses Taught at UBC*

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
1995	PCTH 402	24	2	10	10	10	
1995-1998	PCTH 305	10	55	10			
1995-1998	PCTH 404	5	10	5			
1995-1998	PCTH 425	6	160	6			
1996-	PCTH 400	2	15	1			
1996-1998	PHAR 545	3	15	2			
1997-	PRIN A (Med)	48	8		48		
1997-	PRIN B (Med)	30	8		30		
1997-	MEDI 570	3	10	3			
1997-2000	PCTH 448	2	20	2		10	
1997-	PRIN 401	1	300	1			
2006-	PCTH 325	3	70	3			

(c) *Graduate Students Supervised*

Student Name	Program Type	Year		Principal Supervisor	Co-Supervisor(s)
		Start	Finish		
Yajun Ni	Ph.D	1993	1995	G. Osol	I. Laher
George Wellman	Ph.D.	1993	1995	J. Brayden	I. Laher
Regent Laporte	Ph.D.	1989	1995	I. Laher	
Andrew Ding	M.Sc.	1993	1995	J.A. Bevan	I. Laher

Peter Skarsgard	Ph.D.	1995	2000	B.M. McManus	C. van Breemen I. Laher
Sandra Tam	M.Sc.	1996	1998	I. Laher	
Eugene Lam	M.Sc.	1997	2000	I. Laher	
Amy Liu	M.Sc.	1998	2001	I. Laher	B.M. McManus
Farzad Moien Afshari	M.Sc.	2000	2002	I. Laher	
Nicola Bai	M.Sc.	2002	2004	I. Laher	S. van Eeden
Farzad Moien Afshari	Ph.D.	2002	2008	I. Laher	
Mohammad Mahmudur Rahman	M.Sc.	2004	2006	I.Laher	
Sharzad Elmi	M.Sc.	2005	2008	I.Laher	
Nada Salam	Ph.D.	2005	2012	I.Laher	
Manasi Vadhavkar	M.Sc.	2007	2009	I. Laher	L. Stothers
Mohammad Badran	M.Sc.	2011	2013	I.Laher	
Mohammad Badran	Ph.D.	2013			

(d) *Continuing Education Activities*

Attended *IDEAL* Workshop on Medical Student Assessment (Hong Kong, October 2003)

Attended *Medical Council of Canada* Workshop on Assessment (Vancouver, February 2005)

Attended *IDEAL* Workshop on Medical Student Assessment (Adelaide, Australia, February 2005)

Attended *IDEAL* Workshop on Medical Student Assessment (Khartoum, Sudan, November 2007)

(e) *Visiting Lecturer (indicate university/organization and dates)*

Visiting Associate Professor, University of Vermont.

Visiting Professor, University of Vermont

Visiting Professor, University of Angers, France (2007-2007)

Visiting Professor, University of Angers, France (2010-2010)

(f) *Other*

Post-doctoral Fellows:

Dr. Virginia Lemos (2005-2006) Associate Professor at the Department of Physiology and Biophysics from Instituto de Ciencias Biologicas (Biological Sciences Institute) at the Universidade Federal of Minas Gerais (Federal University of Minas Gerais), Brazil

Dr. Steyner Cortes (2005-2006): Associate Professor at the Department of Pharmacology from Instituto de Ciencias Biologicas (Biological Sciences Institute) at the Universidade Federal of Minas Gerais (Federal University of Minas Gerais), Brazil

Dr. Saeid Golbidi (2007-2008) Assistant Professor, Department of Pharmacology, Kashan University of Medical Sciences, Kashan, Iran

Visiting Scientists

Mr. Henrik Houmann Petersen, Medical Student, University of Aarhus, Denmark. 2000-2001

Ms. Emma Kenyon, Co-op student from the University of London (Kings College, Department of Pharmacology). 1999-2000.

Dr. Hiroshi Washio, Professor (Tokyo University) 2001-2004.

Dr. Shung Lee, Surgery Resident (Vancouver General Hospital), UBC. 2001-2002.

Dr. Keith Baxter, Surgery Resident (Vancouver General Hospital), UBC. 2002-2003.

Dr. Koroush Afshar, Urology Resident (St. Paul's Hospital) 2002-2003.

Dr. Masanori Fukazawa (Research Scientist, Chugai Pharmaceutical Co, Japan) 2003-2003

Dr. Tomohisa Ishikawa. Associate Professor, Dept. Pharmacology (University of Shizuoka) 2004-2004

Dr. Venkat Gopalakrishnan, Professor (University of Saskatoon). 2004-2004.

Dr. Urmilla Shinde, Post-Doctoral Fellow (University of Saskatoon). 2004-2004.

Mr. Alex Yau Chi Chen, Graduate Student (Chinese University of Hong Kong at Shatin) 2004-2004.

Dr. Majid Khazaei, Graduate Student (University of Isfahan, Iran) 2004-2005

Ms. Erika Andersson (University of Stockholm, Sweden) 2005-2005

Dr. Henrik Houmann Petersen, Physician - Scientist, University of Aarhus, Denmark.
2006-2006

Ms. Calista Tan, Exchange Student (Nanyang Technological University, Singapore) 2006-2007

Dr. Ziba Rajaei, Graduate Student (University of Isfahan, Iran) 2007-2007

Mr. Zain G. Hashimi, Medical Student (Aga Khan University, Pakistan) 2008-2008

Graduate Student Thesis Committees:

TITLE	THESIS
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Yajun Ni (University of Vermont, Department of Physiology and Biophysics, 1993-1995).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. George Wellman (University of Vermont, Department of Pharmacology, 1992-1995).
<u>Thesis Supervisor:</u>	Ph.D. Thesis for Dr. Regent Laporte (University of Vermont, Department of Pharmacology, 1985-1995).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Andrew Ding (University of Vermont, Department of Pharmacology, 1993-1995).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Li Li. (The University of British Columbia, Department of Pharmacology and Therapeutics, 1995).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Roshanak Rahimian. (The University of British Columbia, Department of Pharmacology and Therapeutics, 1996).
<u>Committee Member:</u>	M.Sc. Thesis for Mr. Wing Lim Chow. (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 1996).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Paul McDonald. (The University of British Columbia, Department of Pathology and Laboratory Medicine, 1996).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Mark Nazer. (The University of British Columbia, Department of Pharmacology and Therapeutics, 1996).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Rending (Linda) Xu. (The University of British Columbia, Department of Pharmacology and Therapeutics, 1997).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Natalia Yakubovich. (The University of British Columbia, Department of Physiology, 1998-2001).

<u>Committee Member:</u>	Ph.D. Thesis for Ms. Emi Arikawa. (The University of British Columbia, Division of Pharmacology, Department of Pharmaceutical Sciences, 1998).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Yi He (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 1999).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Denise Galipeau. (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 1999).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Andrea Bardell. (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 1999).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Maria Walker. (The University of British Columbia, Department of Pharmacology and Therapeutics, 1999).
<u>University Examiner:</u>	Ph.D. Thesis for Mr. James Hennan (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2000).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Tania Szado. (The University of British Columbia, Department of Pharmacology and Therapeutics, 1999).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Sonia Franciosi. (The University of British Columbia, Department of Pharmacology and Therapeutics, 2000).
<u>Department Examiner:</u>	M.Sc. Thesis for Mr. Daniel Leung. (The University of British Columbia, Department of Pharmacology and Therapeutics, 2000).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Robbin B Burns (The University of British Columbia, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, 2000).
<u>Committee Member:</u>	M.Sc. Thesis for Mr. Jonathan Choy. (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2001).
<u>Committee Member:</u>	M.Sc. Thesis for Mr. Dake Qi. (The University of British Columbia, Department of Pharmacology and Therapeutics, 2001).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Willmann Liang. (The University of British Columbia, Department of Pharmacology and Therapeutics, 2001).
<u>Thesis Examiner:</u>	M.Sc. Thesis for Ms. Christine Binns (The University of British Columbia, Department of Medicine, Experimental Medicine Program, 2001).
<u>University Chair.</u>	Ph.D. Thesis for Ms. Lucie Marzban (The University of British Columbia, Department of Pharmacology, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2001).

<u>University Examiner:</u>	Ph.D. Thesis for Mr. Eric Loucks. (The University of British Columbia, Department of Pharmacology and Therapeutics, 2002).
<u>University Examiner</u>	Ph.D. Comprehensive Exam for Mr. Paul Cheung (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2002).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Pauline Dan (The University of British Columbia, Department of Physiology, 2002).
<u>University Examiner:</u>	Ph.D. Thesis Exam for Mr. Chris Carthy (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2002).
<u>University Chair:</u>	Ph.D. Thesis Exam for Ms. Donna Lang (Department of Neuroscience, Faculty of Medicine, 2002).
<u>University Examiner:</u>	Ph.D. Comprehensive Exam for Ms. Jodene Eldstrom (The University of British Columbia, Department of Physiology, 2002).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Lally Chan (The University of British Columbia, Department of Pharmacology and Therapeutics, 2003).
<u>University Chair.</u>	Ph.D. Thesis for Mr. Sam Au Yeung (The University of British Columbia, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, 2003).
<u>Committee Examiner:</u>	Ph.D. Comprehensive Exam for Mr. Jonathan Choy (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2003).
<u>Departmental Examiner:</u>	M.Sc. Thesis for Dr. Gurdial Singh Mattu (The University of British Columbia, Department of Pharmacology and Therapeutics, 2003).
<u>University Examiner:</u>	M.Sc. Comprehensive Exam for Mr. Kenny WJ Lee (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2003).
<u>University Examiner:</u>	Ph.D. Thesis Exam for Dr. Kuo-Hsing Kuo (Department of Anatomy and Cell Biology, Faculty of Medicine, 2003).
<u>University Examiner:</u>	Ph.D. Thesis Exam for Ms. Linda Yip (Department of Physiology, Faculty of Medicine, 2004).
<u>University Examiner:</u>	Ph.D. Thesis for Mr. Caly Chien (The University of British Columbia, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, 2004).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Arwen T Hunter (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2004).
<u>University Chair:</u>	Ph.D. Thesis Exam for Ms. Pauline Dan (Department of Physiology, Faculty of Medicine, 2004).

<u>Committee Member:</u>	M.Sc. Thesis for Mr. Jason Grebely (The University of British Columbia, Department of Pharmacology and Therapeutics, 2004).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Linda Tran (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2004).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Rani Cruz (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2004).
<u>University Examiner:</u>	Ph.D. Thesis for Ms. Irem Mueed (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2005).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Ehab Mohamed (The University of British Columbia, Department of Pharmacology and Therapeutics, 2005).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Tony Kelly (The University of British Columbia, Department of Physiology, 2005)
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Harish Vasudevan (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2005)
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Prabhakara Nagareddy (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2005)
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Girish Kewalramani (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2005)
<u>Committee Member:</u>	Ph.D. Thesis for Dr. Harout Tossonian (The University of British Columbia, Department of Pharmacology and Therapeutics, 2005).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Linda Tran (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2004).
<u>University Chair:</u>	Ph.D. Thesis for Ms. Erin Maclachlan (The University of British Columbia, Department of Chemistry, 2006).
<u>University Examiner:</u>	Ph.D. Thesis for Ms. Nana Rezai (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2006).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Daniel Cheuk Hang Kwan (The University of British Columbia, Department of Cellular & Physiological Sciences, 2006).
<u>University Chair:</u>	Ph.D. Thesis for Dr. Min Li (The University of British Columbia, Faculty of Dentistry, 2007).
<u>University Chair:</u>	M.Sc. Thesis for Dr. Mostafa Elmeitiri (The University of British Columbia, Department of Surgery, Faculty of Medicine, 2007).

<u>Committee Member:</u>	Ph.D. Thesis for Ms. Geetanjali Kharmate (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2008).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Alex Chang (The University of British Columbia, Department of Medicine, Experimental Medicine Program, 2008).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Prasanth Puthanveetil (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2008)
<u>University Examiner</u>	Ph.D. Thesis for Mr. Balraj Singh Heram (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2008)
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Lisa Ang (The University of British Columbia, Department of Pathology and Laboratory Medicine,, 2008)
<u>University Chair:</u>	Ph.D. Thesis for Ms. Tammy Lee Romanuik (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2008).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Subrata Deb (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2009).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Carol Yu (The University of British Columbia, Department of Pharmacology and Therapeutics, 2009).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Apreeta Sharma (The University of British Columbia, Department of Pharmacology and Therapeutics, 2009).
<u>University Examiner:</u>	Ph.D. Thesis for Mr. Aaron Joe (The University of British Columbia, Department of Experimental Medicine, Faculty of Medicine, 2009).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Bernhard Lehnertz (The University of British Columbia, Department of Experimental Medicine, Faculty of Medicine, 2009).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Fang Wang (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2009).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Ibrahim Mustafah (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2009).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Melissa Glier (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2009).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Sajad Amin War (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2010).

<u>University Examiner:</u>	Ph.D. Thesis for Mr. Min-Suk Kim (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2010).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Eric Lin Jing Tsai (The University of British Columbia, Department of Cellular and Physiological Sciences, 2010).
<u>University Examiner:</u>	Ph.D. Thesis for Mr. Marco Perez Garcia (The University of British Columbia, Department of Anesthesia, Pharmacology and Therapeutics, Faculty Medicine, 2010).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Kangbin Zhou (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2010).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Samir Alkabile (The University of British Columbia, Department of Medicine, Experimental Medicine Program, 2010).
<u>Committee Chair:</u>	Ph.D. Thesis for Mr. Kristen Wong (The University of British Columbia, Department of Chemical and Biological Engineering, 2010).
<u>Committee Member:</u>	MSc. Thesis for Ms. Nazarin Roshan Moniri (The University of British Columbia, Department of Medicine, Experimental Medicine Program, 2010).
<u>University Chair:</u>	Ph.D. Thesis for Ms. Kelley Ann Bromley-Brits (The University of British Columbia, Department of Medicine, Neuroscience Program, 2011).
<u>Committee Member:</u>	M.Sc. Thesis for Ms. Rika Aleliunas (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2011).
<u>University Examiner:</u>	Ph.D. Thesis for Mr. Brian Wong (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2011).
<u>Committee Member:</u>	M.Sc. Thesis for Mr. Mohammad Mynol Islam Vhuyian (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2010).
<u>Committee Member:</u>	Ph.D. Thesis for Mr. Dahai Zhang (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2010).
<u>University Chair:</u>	Ph.D. Thesis for Ms. Maria N. Fairbank (The University of British Columbia, Department of Cellular and Physiological Sciences, 2012).
<u>University Examiner:</u>	Ph.D. Thesis Exam for Mr. Frank K. Huynh (Department of Physiological and Cellular Sciences, Faculty of Medicine, 2012).
<u>University Examiner:</u>	Ph.D. Thesis Exam for Ms. Wendy A. Boivin (Department of Pathology and Laboratory Medicine, Faculty of Medicine, 2012).

<u>University Examiner:</u>	Ph.D. Thesis for Mr. Hesham Soliman (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2012).
<u>University Examiner:</u>	Ph.D. Thesis Exam for Mr. David Chia-Hsiang Lin (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2012).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Jessica Yuen (The University of British Columbia, Department of Medicine, Experimental Medicine Program, 2013).
<u>Committee Member:</u>	Ph.D. Thesis for Ms. Pei-Ling (Amy) Chiu (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2014).
<u>University Chair:</u>	Ph.D. Thesis for Mr. Iman Mansoor (The University of British Columbia, Department of Electrical and Computer Engineering, 2014).
<u>Committee Member:</u>	M.Sc. Thesis Exam for Mr. Mehul Sharma (The University of British Columbia, Department of Pathology and Laboratory Medicine, 2014).

SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) Areas of special interest and accomplishments

PHARMACOLOGY OF AUTOREGULATION
 AUTONOMIC PHARMACOLOGY
 VASCULAR SMOOTH MUSCLE
 CEREBROVASCULAR PHARMACOLOGY

(b) Research or equivalent grants

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Heart & Stroke Foundation Of Canada	Traineeship.	\$9,000	1978-1983	I. Laher	
University of Vermont	Postdoctoral Fellowship.	\$16,000	1983-1984	I. Laher	
Heart & Stroke Foundation Of Canada	Postdoctoral Fellowship.	DECLINE	1983-1984	I. Laher	

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Heart & Stroke Foundation Of Canada	Postdoctoral Fellowship.	\$18,000	1984-1986	I. Laher	
American Heart Association	Postdoctoral Fellowship.	DECLINE	1984-1986	I. Laher	
American Heart Association	Postdoctoral Fellowship.	18,000	1986-1987	I. Laher	
National Institutes of Health	Grant In Aid: <i>Stretch activates vascular myogenic tone and Ca²⁺entry.</i>	350,000	1989-1995	I. Laher	
Medical Research Council	Operating Grant: <i>The sarcoplasmic reticulum buffers Ca²⁺ -entry in blood vessels.</i>	115,000	1994-1997	I. Laher	
Heart & Stroke Foundation Of Canada	Operating Grant: <i>Calcium release in cerebral arteries.</i>	175,000	1995-1998	I. Laher	
American Heart Association	Grant In Aid: <i>The sarcoplasmic reticulum as a modulator of vascular tone.</i>	20,000	1995-1996	I. Laher	
Heart & Stroke Foundation Of Canada	Operating Grant: <i>Estrogen and vasodilation of coronary arteries.</i>	80,300	1997-1999	I. Laher	
Heart & Stroke Foundation Of BC & Yukon	Operating Grant: <i>Endothelial and smooth muscle cell injury in the pathogenesis of transplant vascular disease</i>	120,000	1998-2001	B. McManus	C. van Breemen, I. Laher, E. Moore, U. Steinbrecher, V. Dorino, K. Zis
Canada Foundation for Innovation	New Opportunities Grant (Operating Grant): <i>Signal transduction in resistance arteries.</i>	120,000	1998-2001	I. Laher	

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Heart & Stroke Foundation Of BC & Yukon	Operating Grant <i>Signaling in initiation and acceleration of lipid-rich transplant vascular disease.</i>	160,000	1999-2003	B. McManus	C. van Breemen, I. Laher, U. Steinbrecher, V. Dorino, K. Zis
Heart & Stroke Foundation Of Canada	Operating Grant: <i>Estrogen regulates endothelial function.</i>	129,000	1999-2002	I. Laher	
Heart & Stroke Foundation Of Canada	Operating Grant: <i>Novel pathogenesis and therapies for transplant vascular disease.</i>	DECLINE	1999-2001	I. Laher	P. Skarsgard
Canada Foundation for Innovation	Operating Grant: <i>Novel pathogenesis and therapies for transplant vascular disease.</i>	157,137	1999-2002	I. Laher	P. Skarsgard
Canada Foundation for Innovation	Operating Grant (PMAC Award): <i>Estrogen and endothelial signaling.</i>	146,550	1996-1999	C. van Breemen	I. Laher X. Wang
Heart & Stroke Foundation Of Canada	Operating Grant: <i>Ca²⁺ gradients in vascular smooth muscle: Mechanisms and function.</i>	118,400	1999-2001	C. van Breemen	I. Laher E. Moore
Heart & Stroke Foundation Of BC & Yukon	Program Grant: <i>Signaling in initiation and acceleration of lipid-rich transplant vascular disease.</i>	700,000	1999-2003	B. McManus	C van Breemen I. Laher E. Moore U. Steinbrecher V. Duronio K. Dorovini-Zis
Japan Society For The Promotion Of Science	Research Collaboration (Travel Grant): <i>Mechanotransduction in smooth muscle.</i>	250,000 Japanese Yen (~\$3,000CAD)	2002-2003	I. Laher	

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Heart & Stroke Foundation Of BC & Yukon	Operating Grant: <i>Coronary artery vasomotion and hypertrophic cardiomyopathy.</i>	85,700	2002-2005	I. Laher	
Heart & Stroke Foundation Of BC & Yukon	Operating Grant: <i>Air pollution and atherogenesis.</i>	75,000	2003-2006	S. van Eeden	I. Laher
Hong Kong Research Grant Council	Operating Grant: <i>Long-term effect of ovariectomy and raloxifene (SERM) replacement therapy on endothelial function and on regulation of smooth muscle ion channels.</i>	789,000 HK\$ (~\$142,000 CAD)	2003-2005	Y. Pi Huang	I. Laher XQ Yao
Canada Foundation for Innovation	Operating Grant: <i>Granzyme B: Role in transplant vascular disease and associated vascular dysfunction.</i>	\$81,000	2004-2007	D. Granville	I. Laher
Heart & Stroke Foundation Of BC & Yukon	Operating Grant: <i>Cigarette smoking and resistance artery function.</i>	\$91,413	2004-2007	I. Laher	
Heart & Stroke Foundation Of BC & Yukon	Operating Grant: <i>Cellular mechanisms of vascular dysfunction in human diabetes.</i>	\$103,740	2004-2007	C. van Breemen	I. Laher
Canadian Diabetes Association	Operating Grant: <i>Exercise improves coronary artery function in obese db/db mice.</i>	\$74,891	2005-2007	T.J. Podor	I. Laher
Heart & Stroke Foundation Of BC & Yukon	Operating Grant: <i>Lifestyle modifications improve coronary artery function in type 2 diabetes.</i>	\$87,528	2006-2009	I. Laher	

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Heart & Stroke Foundation Of BC & Yukon	Operating Grant <i>Vascular function following spinal cord injury: Effects of blood pressure instability and exercise.</i>	\$75,853	2010-2013	A. Krassiokov	I.Laher M. Ramer
Canadian Institutes of Health (CIHR)	Team Grant: <i>Respiratory sleep disorders research team</i>	\$286,626	2010-2015	N.Ayas	F. R. Almeida S. Bryan S. Fels J.M. Fitzgerald J.A. Fleetham J.A. Fleming B.Kwiatkowska I. Laher A.Lowe G.B.J. Mancini C.A. Marra F. Ryan A.J. Sanford W.A. Sheel S.F. van Eeden
Christopher and Dana Reeve Foundation	Team Grant: <i>Manipulating COX-2 signaling to improve the cardiovascular outcome of SCI.</i>	\$149,460	2011-2013	A. Krassioukov	I. Laher M. Ramer
Canadian Institutes of Health (CIHR)	Team Grant: <i>Improving cardiovascular health for Canadians living with spinal cord injury: effects of exercise and targeted education</i>	\$380,000	2012-2017	A. Krassioukov	S.Bryan C.Craven D. Ditor J. Eng I. Laher T.Lam M. MacDonald K. M. Ginis M. Ramer M. Verrier

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Canadian Institutes of Health (CIHR)	Operating Grant: <i>Developmental Exposure to Maternal Obesity and Programming of Vascular Disease</i>		2014-2019	A. Devlin	I.Laher

(c) *Research or equivalent contracts*

Granting Agency	Subject	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Chugai Pharmaceuticals	<i>Effect of BO-653 on oxidized LDL-induced endothelial dysfunction in conductance arteries of rats</i>	25,000	2002	I. Laher	U. Steinbrecher
Faculty of Medicine (UBC) Summer Student Internship Program	<i>Integrated Pharmacology Cases as Self-Directed Learning Tools</i>	4,500	2008	I. Laher J. Shabbits S. Bardal	
Faculty of Medicine (UBC) Summer Student Internship Program	<i>Developing problem sets for formative assessment</i>	4,500	2009	I.Laher	

(d) *Invited Presentations*

1. Symposium on Vascular Smooth Muscle (International Physiological Society) held at Banff, Canada, 1986.

2. Vascular Neuroeffector Mechanisms meeting held at Melbourne, Australia 1987.
3. International Symposium on Calcium Antagonists held at New York Academy of Sciences, New York, USA 1987.
4. American Physiological Society Symposium on Smooth Muscle, Mayo Clinic, Rochester, MN, 1989.
5. The Human Brain Circulation: Functional Changes in Disease. Totman Conference on Human Cerebrovascular Research, Basin Harbor Club, Vergennes, Vermont 1992.
6. The Fourth International Symposium on Resistance Arteries, Stowe, Vermont 1994.
7. The 14th International Congress of Geographic Medicine & 15th Iranian Congress of Physiology & Pharmacology. Shiraz, Iran, November, 2001.
8. Department of Pharmaceutical Sciences, University of Isfahan, Isfahan, Iran. November 2001.
9. Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran. November 2001.
10. Department of Pharmacology, University of Iran Medical School, Tehran, Iran. November 2001.
11. *“Regulatory role of mechanical stress response in cellular function—development of new drugs and tissue engineering”*. Mechanotransduction Congress Symposium of the 74th Japanese Pharmacological Society, Kumamoto, Kyushu Island, Japan, March 2002.
12. *“Resistance artery function in health and disease”*. Department of Pharmacology, Faculty of Pharmaceutical Sciences, University of Shizuoka, Shizuoka City, Japan March 2002
13. *“PKC and Gap Junctions in the modulation of vascular myogenic tone”*. Departments of Physiology and Biophysics, University of Aarhus, Denmark, April 2002.
14. *“Ca²⁺-sensitization during myogenic activation of rat cerebral arteries”*. Myogenic 2002 Centennial Symposium: Trapp Family Lodge, Stowe, Vermont, June 2002
15. *“Transplant vascular disease in rat cardiac allografts”*. Department of Pharmacology, College of Medicine, University of Vermont, June 2002.
16. *“Effect of cyclosporine in transplant vascular disease”*. Department of Occupational Diseases, Yangpu District Central Hospital, Shanghai, Peoples Republic of China, August 2002.
17. *“Role of nitric oxide in transplant vascular disease”*. Department of

- Pharmacology, National University of Singapore August 2002.
18. "*Effects of cyclosporine in transplant vascular disease in rat cardiac allografts*". Department of Physiology, Chinese University of Hong Kong, August 2002.
 19. "*Signaling mechanisms in vascular mechanotransduction*", Department of Pharmacology, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan, October 2002.
 20. "*Mechanisms regulating arterial myogenic tone*". Department of Molecular Cardiology, Research Institute of Angiocardiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, October 2002.
 21. "*Signaling mechanisms regulating resting arterial diameter*". Chugai Pharmaceutical Company, Gotemba, Shizuoka, Japan, October 2002.
 22. "*Cyclosporine restores arterial function in transplant vascular disease*". Department of Pharmacology, Kuwait University, Kuwait, December 2002.
 23. Invited Speaker at Symposium on "Inflammatory Heart Diseases and Cardiac Failure" at the 46th Annual Meeting of the Canadian Federation of Biological Societies. Ottawa, Canada, June 2003.
 24. Invited Speaker at the Northwest Atherosclerosis Club Meeting, McDonald Research Centre, St. Paul's Hospital, Vancouver, Canada [*Pharmacology of mouse coronary arteries: relevance of mouse models of disease.*] November 2003.
 25. "*The endothelial regulation of vascular health and disease*" Department of Physiology and Pharmacology, University of New South Wales, Sydney, Australia. March 2005.
 26. "*Lifestyle modifications improve vascular dysfunction in a mouse model of type 2 diabetes*". University of Washington, Department of Pathology, Seattle, WA. September 2005
 27. "*Exercise reverses vascular dysfunction in type 2 diabetes*" Invited Speaker at the 17th Iranian Congress of Physiology and Pharmacology. Kerman University of Medical Sciences, Kerman, Iran. October 2005
 28. "*Lifestyle modifications improve vascular function in diabetes*". Invited presentation at Angers University, France. May, 2007
 29. "*Use of R-Type Questions in Assessment of Medical Students*". Invited presentation by the Faculty of Medicine Assessment Working Group, University of al-Jazirah, Wad Madani, Sudan, November 2007

30. “Assessing Medical Student’ Clinical and Scientific Reasoning & Decision Making Abilities Using R-type Items” IDEAL Medical Exam Item Writing Workshop, Khartoum, Sudan , November 2007
31. “Exercise improves coronary artery function in diabetic mice”. Invited presentation at The 9th International Symposia on Resistance Arteries 2008 (Hamilton Island, Australia) April , 2008.
32. “Type 2 Diabetes: Why exercise?” Invited presentation at the Department of Pharmacology, Faculty of Medicine, The University of Vermont (Burlington, VT). October, 2008.
33. “Exercise improves vascular function in type 2 diabetes: some mechanistic insights”. Invited presentation at the 19th Iranian Congress of Physiology and Pharmacology (Tehran, Iran). November 2009.
34. “Exercise induced molecular changes in vascular function in type 2 diabetes” Invited presentation at the Department of Physiology, Esfahan University (Esfahan, Iran). November 2009.
35. “Exercise in type 2 diabetes: some mechanistic insights” Invited presentation at 16th World Congress of Basic and Clinical Pharmacology (IUPHAR—WorldPharma 2010) (Copenhagen, Denmark; July 2010).
36. “Moderate Levels of Exercise Improve Coronary Artery Function in a Mouse Model of Type 2 Diabetes”. Invited presentation at 9thWorld Congress For Microcirculation. Paris, France (September 2010).
37. “Beneficial effects of exercise in the db/db mouse model of type 2 diabetes” Invited presentation at the University of Angers, France (September, 2010).
38. “Mechanisms of improved vascular function following modest exercise in type 2 diabetic mice” Invited presentation at the The 10th International Symposia on Resistance Arteries 2011, Rebild, Denmark (May 2011).
39. ““Type 2 Diabetes Mellitus: Why Exercise?” Invited presentation at the Department of Pharmacology, Faculty of Medicine, Kuwait University (February 2014).
40. “Improving endothelial function in type 2 diabetes” Invited presentation at 17th World Congress of Basic and Clinical Pharmacology. International Union of Basic and Clinical Pharmacology (IUPHAR). (Cape Town, South Africa, July 2014).
41. “Exercise reduces oxidative stress and improves vascular function in the db/db mouse model of type 2 diabetes” Invited presentation at 5th International Congress on Cell Membranes and Oxidative Stress. Isparta, Turkey (September, 2014)

(e) *Other Presentations*

Invited Lecture “Pharmacology of Osteoporosis” at the Department of Pharmacology, Ross University School of Medicine, Commonwealth of Dominica, West Indies, March 2003.

(f) *Conference Participation (Organizer, Keynote Speaker, etc.)*

Organizer of 1st. New England Smooth Muscle Society Meeting, Burlington, VT, 1993.

Joint Organizer of the International Symposium on Signal Transduction in Endothelial Cells, Vancouver, Canada, 1996.

Chair of Symposium on “*Cerebral Artery Pharmacology and Physiology*”—5th Internet World. Congress on Biomedical Sciences, December 7-16, 1998.

Keynote Speaker at Symposium on Vascular Myogenic Tone at Congress Symposium “*Regulatory role of mechanical stress response in cellular function—development of new drugs and tissue engineering*” of the 74th Japanese Pharmacological Meetings, Kumamoto, Japan, March 2002.

State of the Art Lectures at The 14th International Congress of Geographic Medicine & 15th Iranian Congress of Physiology & Pharmacology. Shiraz, Iran, November 2001.

Organizing Committee Member of “*Frontiers in Cardiovascular Sciences 2003 Conference*”, Vancouver, Canada, February 2-4, 2003.

Organizing Committee Member for the 8th International Society for Resistance Arteries (ISRA) Meeting. Angers, France, May 2004.

Chair, Plenary Session on Ionic Control of Tone for the 8th International Society for Resistance Arteries (ISRA) Meeting. Angers, France, May 2004.

Co-Leader, Workshop “*Human resistance arteries and pathology; Investigations of resistance arteries at the bedside. Information for clinical decisions*”. 8th International Society for Resistance Arteries (ISRA) Meeting. Angers, France, May 2004.

Joint Organizer and Co-Chair of Division of Systems and Integrated Symposium “*20 Years of Calcium Imaging: A Revolution in Cell Physiology to Dye For*”, Experimental Biology, San Diego, USA (April, 2005)

Organizer and Chair of Symposium “*Pharmacology of the sarcoplasmic reticulum in smooth muscle*” at The 15th International Union of Pharmacology (IUPHAR), Beijing, China (July 2006).

International Scientific Advisory Committee Member for the 9th International Society for Resistance Arteries (ISRA) Meeting. Sydney, Australia (February 2008).

Invited presentation on “*Assessing Medical Student’ Clinical and Scientific Reasoning & Decision Making Abilities Using R-type Items*” at IDEAL Medical Exam Item Writing Workshop, Khartoum, Sudan (November 2007)

Organizer and Chair of Division of Systems and Integrated Symposium “*The Obesity Epidemic: Pharmacological Challenges*”, Experimental Biology, San Diego, USA (April, 2008).

Organizer and Chair of IUPHAR Symposium “*Antioxidants as Therapeutic Agents. Part 1: Systems Biology*”. International Congress of Pharmacology WorldPharma 2010 Convention. Copenhagen, Denmark (July 2010).

Organizer and Chair of IUPHAR Symposium “*Antioxidants as Therapeutic Agents. Part 2: Cardiovascular Health*”. International Congress of Pharmacology WorldPharma 2010 Convention. Copenhagen, Denmark (July 2010).

Organizer and Chair of IUPHAR Symposium “*Antioxidants as Therapeutic Agents. Part 3: Pathophysiology*”. International Congress of Pharmacology WorldPharma 2010 Convention. Copenhagen, Denmark (July 2010).

International Scientific Advisory Committee Member for the 10th *International Society for Resistance Arteries (ISRA) Meeting*. Rebild, Denmark (May, 2011).

Organizer and Chair of ASPET Symposium “*Systems Biology of Oxidative Stress and Therapeutic Implications*.” Experimental Biology, Washington, DC, USA (April 2011).

Organizer and Chair of ASPET Symposium “*Sleep Apnea: A Sleeping Giant in Disease Pathologies*” Experimental Biology, Boston, MA, USA (April 2013).

Organizer and Chair of IUPHAR Symposium “*Obesity: Basic and Clinical Pharmacology*”. 17th World Congress of Basic and Clinical Pharmacology WorldPharma 2014 Convention. Cape Town, South Africa (July, 2014)

SERVICE TO THE UNIVERSITY

(a) *Memberships on committees, including offices held and dates*

YEAR	NAME:
1996-2001	GI/Nutrition Module Committee for Medical and Dental School Problem Based Learning Curriculum.
1996-	Department Standing Committee on Promotion and Tenure.
1996-	Life Sciences Library Advisory Committee, Woodward Biomedical Library.
1997-2006	Department Graduate Advisor.
1997-1999	Vancouver Vascular Biology Research Center, Steering Committee
1998-2006	Cardiovascular Module Committee for Medical and Dental School Problem Based Learning Curriculum (Week Co-captain)
1998-2006	Pharmacology Representative for P2P2 Block for Medical and Dental School Problem Based Learning Curriculum.

YEAR	NAME:
1999-2006	Cardiovascular Module for Medical and Dental School Problem Based Learning—Week Co-Captain.
1999-2001	Departmental Representative on Faculty of Medicine Retreat on Research.
1999-2000	Acting Block Head, Cardiovascular Medicine Module, P2P2 Block of Medical and Dental School Problem Based Learning Curriculum.
1999-2004	Faculty of Medicine Representative to the Faculty of Pharmaceutical Sciences.
1999-2000	Faculty of Medicine Representative to the Faculty of Science.
2000-2004	Faculty Advisor to Medical and Dental Students (Undergraduate).
2001-2003	Member of MD/PhD Advisory Committee
2001-2006	Member of Faculty of Medicine Graduate Education Committee
2001-	Chair, Principles of Biology Module, P2P1 (PRIN 401 Block of Medical and Dental School Problem Based Learning Curriculum).
2001-	Member, Students Promotions Committee (Years 1 and 2) Medical and Dental School.
2001-	Member, Undergraduate Medical and Dental Curriculum Education Committee.
2002-	Consolidation Week Co-Captain. Principles of Human Biology, Problem Based Learning Curriculum for Medical and Dental Students.
2002-2003	Member, Curriculum Overview Committee (Now Disbanded).
2002-2003	Member, Accreditations and Approvals Subcommittee for Medical School Expansion.
2002-2004	Member, Curriculum Year 2 and 2 Subcommittee of the MD Undergraduate Expansion Task Force.
2003-2004	Departmental Representative to the Faculty of Science
2003-2003	Search Committee for Instructor Recruitment, Problem Based Learning Curriculum of the Faculty of Medicine.
2004-2004	Member, Medical and Dental Student Remediation Working Group.
2004-2005	Member, Search Committee for UBC Diversity Advisor—Race and Ethnicity.
2004-	Chair, Year 1 Medical and Dental Student Support and Development Committee.
2004-2005	Search Committee for Case Writing Director, Problem Based Learning Curriculum of the Faculty of Medicine.
2005-2005	Member, promotion and tenure committee, Department of Anesthesia, Faculty of Medicine (for Dr. Dr. Mark Ansermino).
2005-2005	Search Committee Member for Associate Head, Department of Anesthesia, Pharmacology and Therapeutics.
2007-2007	Search Committee for Instructor Recruitment, Problem Based Learning Curriculum of the Faculty of Medicine.
2007-2009	Chair, Department of Pharmacology and Therapeutics, Pharmacology Teaching Committee.
2007-2008	Faculty of Medicine Year 1 and 2 Curriculum Evaluation Working Group.
2008-	Committee Member, UBC Faculty of Medicine Social Justice Core Team.
2008-	Committee Member, Faculty of Medicine MD Undergraduate Curriculum Faculty Appointments Committee.

YEAR	NAME:
2009-	Chair, Year 2 Medical and Dental Student Support and Development Committee.
2009-	Director for MD Year 1 Foundations of Medicine Course.
2010-	Committee Member of the MMI Question Writing Group, Faculty of Medicine, UBC.
2010-	Co-Chair, MMI (Multiple Mini Interviews) Committee of UBC MD Undergraduate Admissions Office.
2010-	Member of Working Group on Curricular Governance of Dean's Task Force on Medical Curriculum Renewal.
2010-	Member of Working Group on Social Responsibilities and Accountability of Dean's Task Force on Medical Curriculum Renewal.
2011-2011	Search Committee Member for Assistant Dean, Student Affairs for the UBC Medical Undergraduate Program (Faculty of Medicine).
2012-2012	Member of Working Group on Curriculum Design of Dean's Task Force on Medical Curriculum Renewal.
2012-2012	Member of Gender and Diversity Advisory Group of the Equity and Professionalism Office (Faculty of Medicine).
2012-2012	Member of Core Cases Working group of MD Undergraduate Curriculum (Faculty of Medicine).
2012-2012	Member of the Pathways and ExCEL space (Extra Curriculum Enhanced Learning) Working group of MD Undergraduate Curriculum (Faculty of Medicine).
2012-2013	Member of the Academic Learning Community Working group of MD Undergraduate Curriculum (Faculty of Medicine).
2012-2013	Member of the Transitions Working group of MD Undergraduate Curriculum (Faculty of Medicine).
2012-2013	Member of the Social Accountability Working group of MD Undergraduate Curriculum (Faculty of Medicine).
2013-	Co-Director of the Foundations of Medical Practice Course (FOMP 415) of MD Undergraduate Curriculum (Faculty of Medicine).

(b) Other service, including dates

2004-2005 Member of Search Committee for Faculty Appointment in Pharmacology Instructor at the University of Northern British Columbia (UNBC)

2010-2010 Member of the Search Committee for faculty Appointment in Pharmacology Instructor at the University of Okanagan (UBC-O)

11. **SERVICE TO THE COMMUNITY**

1999—2012 University Chaplain, UBC (Muslim Students Association)

(a) *Memberships on scholarly societies, including offices held and dates*

American Society of Pharmacology and Experimental Therapeutics (1988 to present).
The Microcirculatory Society (1989 to present).
The Pharmacological Society of Canada (1989 to present).
American Heart Association Council on Circulation (1989 to present).
New England Smooth Muscle Society (1993 to present)
South African Pharmacological Society (2005-present)
International Society for the Scholarship of Teaching and Learning (2005-present)

(b) *Memberships on other societies, including offices held and dates*

(c) *Memberships on scholarly committees, including offices held and dates*

Invited Member, Medical Research Council of Canada Research Grants Committee
(Cardiovascular Research, A) 1997-1998.

Invited Member, Medical Research Council of Canada Research Grants Committee
(Cardiovascular Research, B) 2001-2001.

Member, Canadian Institutes of Health Research (Cardiovascular Sciences Committee C)
2001-2003.

Invited Member, Medical Research Council of Canada Research Grants Committee
(Cardiovascular Research, B) 2003

Representative for Division of Systems and Integrative Pharmacology at Executive
Committee Meetings (ASPET) 2003-

Representative, American Society of Experimental Pharmacology (ASPET) Scientific
Council (2004-2006)

Member, ASPET Systems and Integrative Pharmacology Abstract Competition
Committee 2004—

Invited External Reviewer for National Research Agency –ANR (Agence Nationale de la
Recherche, France) “Young Researchers” (JCJC) Program. 2008-

Member, Canadian Society of Pharmacology and Therapeutics “Education Committee”
2010-

(d) Memberships on other committees, including offices held and dates

Member of the Executive Committee of the Division of Systems and Integrative Pharmacology of the American Society of Pharmacology and Experimental Therapeutics (ASPET) (2003-)

Member of the Canadian Society of Pharmacology and Therapeutics (CSPT) Education Committee (2010-2013)

Chair-Elect for Division for Integrative Systems, Translational and Clinical Pharmacology (Division of American Society of Pharmacology and Therapeutics) 2011-2013.

Chair of Division for Integrative Systems, Translational and Clinical Pharmacology (Division of American Society of Pharmacology and Therapeutics) 2013-2015.

(e) Editorships (list journal and dates)

Editorial Board of "Blood Vessels" 1987-1992.

Editorial Board of "Journal of Vascular Research" 1998-.

Editorial Board of "American Journal of Physiology: Heart and Circulatory Section" 1999-
Kuwait University Experts Referee Panel 2002-

Editorial Board of "Current Cardiology Reviews" 2004-

Guest Editor "American Journal of Physiology: Heart and Circulatory Section—Special
Call of Invited Reviews from the ISRA 2004 Meeting.

Editorial Board for "Advances in Pharmacology" 2008-

Editorial Board for "World Diabetes Journal" 2009-

Editorial Board for "World Journal of Cardiology" 2009-2013

Associate Editor for "Frontiers in Cardiovascular and Smooth Muscle Pharmacology"
2010-

Associate Editor for "Frontiers in Ethnopharmacology" 2010-

Editorial Board for "Advanced Biomedical Research" 2011-

Editorial Board for "CNS Neurosciences and Therapeutics" 2011-

Editorial Board for "World Journal of Translational Medicine" 2011-

Editorial Board for "Scientifica—Vascular Medicine" 2012-

Editorial Board for "Education Matters " (Faculty of Medicine, UBC) 2012-

Editorial Board for "Dataset Papers in Science (Cardiology)" 2012-

Editorial Board for "Journal of Education and Health Promotion" 2012-

Editorial Board for "World Journal of Diabetes" 2012-

Editorial Board for "World Journal of Translational Medicine" 2012-

Editorial Board for "Clinical and Experimental Psychiatry" 2013-

Editorial Board for "British Journal of Pharmaceutical Research" 2013-

Editorial Board for "Journal of Cardiology and Therapy" 2013-

Editorial Board for "Journal of Pharmacology and Drug Metabolism" 2013

f) *Reviewer (journal, agency, etc. including dates)*

Ad-hoc reviewer for:

Acta Diabetologia; Acta Physiologica Scandinavica; American Journal of Physiology (Cell Physiology; Heart and Circulatory Physiology; Regulatory, Integrative and Comparative Physiology); American Journal of Pathology; Antioxidants and Redox Signaling; Atherosclerosis; Basic & Clinical Pharmacology & Toxicology; Biochemical Pharmacology; Blood Vessels; Biological & Pharmaceutical Bulletin; British Journal of Pharmacology; Canadian Journal of Cardiology; Canadian Journal of Physiology and Pharmacology; Carcinogenesis; Cardiovascular Research; Circulation; Circulation Research; Clinical Science; Current Medicinal Chemistry-Cardiovascular and Hematological Agents; European Journal of Pharmacology; FASEB Journal; Hypertension; Gene Therapy (Nature); Journal of Applied Physiology; Journal of Cardiovascular Pharmacology; Journal of Diabetes and its Complications; Journal of Pharmacological Methods; Journal of Cerebral Blood Flow and Metabolism; Journal of Diabetes and Its Complications; Journal of Pharmacology and Experimental Therapeutics; Journal of Urology; Journal of Receptors & Signal Transduction; Journal of Vascular Research; Microvascular Research; Life Sciences; Molecular Interventions; Pharmacology and Therapeutics; Physiology & Behavior; Pediatric Obesity; Stroke; Trends in Cardiovascular Medicine; Trends in Pharmacological Sciences; Urological Research.

Heart and Stroke Foundation of Canada.

Medical Research Council of Canada (Committee Member, Cardiovascular A and C Committees).

Burroughs Wellcome Foundation, UK

The Kidney Foundation of Canada

Reviewer “Internal Review of CIHR Grant Applications” ---UBC applications for CIHR Operating Grant Competition

Canadian Diabetes Association

(g) *External examiner (indicate universities and dates)*

External Examiner:

Ph.D. Thesis for Ms. Vivian Pijuan (University of Miami, Department of Pharmacology, 1990).

University Examiner:

Ph.D. Thesis for Mr. James Hennan (University of British Columbia, Faculty of Pharmaceutical Sciences, 2000).

University Chair: Ph.D. Thesis for Mr. Robbin B Burns (The University of British Columbia, Faculty of Pharmaceutical Sciences, 2000)

University Chair: Ph.D. Thesis for Ms. Lucie Marzban (Department of Pharmacology, Faculty of Pharmaceutical Sciences, 2001).

University Chair: Ph.D. Thesis for Ms. Donna Lang (Department of Neuroscience, Faculty of Medicine, 2002)

University Chair: Ph.D. Thesis for Mr. Sam Au Yeung (The University of British Columbia, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, 2003).

University Chair: Ph.D. Thesis for Ms. Donna Lang (Department of Mr. Tony Kelly, Department of Cellular and Physiological Sciences Faculty of Medicine, 2005).

External Examiner: Ph.D. Thesis for Mr. Lai Ming Yung (Department of Physiology, The Chinese University of Hong Kong, 2008).

University Examiner: Ph.D. Thesis for Mr. Aaron Joe (The University of British Columbia, Department of Medical Genetics, Faculty of Medicine, 2009).

University Examiner: Ph.D. Thesis for Mr. Min-Suk Kim (The University of British Columbia, Division of Pharmacology, Faculty of Pharmaceutical Sciences, 2010).

University Examiner: Ph.D. Thesis for Mr. Marco Perez Garcia (The University of British Columbia, Department of Anesthesia, Pharmacology and Therapeutics, Faculty Medicine, 2010).

External Examiner: Ph.D. Thesis for Mr. Rudo Fiona Mapanga (Stellenbosch University, South Africa)

(h) *Consultant (indicate organization and dates)*

(i) *Other service to the community*
 Muslim Chaplain, UBC (1996-2010)

12. **AWARDS AND DISTINCTIONS**

Awards for Scholarship (indicate name of award, awarding organizations, date)

BC Scholars Award to China Travel Grant (2001-2002)
 Japan Society for the Promotion of Science Fellowship Award (2002-2003)
 UBC Faculty Certificate Program Teaching Scholarship (2005-2006)

Travel Award, University of Angers, France (2007-2007)
Travel Award, University of Angers, France (2010-2010)

OTHER RELEVANT INFORMATION (Maximum One Page)

THESES WRITTEN:

1977: Myocardial Effects of Imidazole. (Partial requirement for B.Sc. (Hons) degree, Chelsea College, University of London, UK). Supervisors: Dr. J.H. McNeill (UBC), Dr. J. Botting and Dr. S. Hart.

1980: Species Differences in the Cardiac Effects of Histamine (Partial requirement for M.Sc. degree in Pharmacology, University of British Columbia). Supervisor: Dr. J.H. McNeill.

1983: A study of the relationship between the Chemical Sensitivity of Smooth Muscle and the Blood Pressure of Genetically Hypertensive Rats. (Partial requirement for Ph.D. degree in Pharmacology, Memorial University of Newfoundland). Supervisor: Dr. C.R. Triggle.

THE UNIVERSITY OF BRITISH COLUMBIA
Publications Record

SURNAME: LAHER FIRST NAME: Ismail DATE: 1 May 2014

1. **REFEREED PUBLICATIONS**

(a) *Journals*

1. Laher I, McNeill JH (1979). Histamine responses in cat heart. *Proc West Pharmacol Soc* 22:419-421
2. Laher I, McNeill JH (1980). Effects of 2-(2-pyridyl) ethylamine (PEA) on the isolated guinea-pig heart. *Agents Actions* 10:417-421
3. Laher I, McNeill JH (1980) Effects of histamine on rat isolated atria. *Can J Physiol Pharmacol* 58:1114-1116
4. Laher I, McNeill JH (1980). Effects of histamine in the isolated kitten heart. *Can J Physiol Pharmacol* 58:1256-1261
5. Rodgers RL, Tenner TE, Laher I, McNeill JH (1980). Interactions of clonidine with chronotropic agents in isolated right atria. *Can J Physiol Pharmacol* 58:23-28,
6. Laher I, McNeill JH (1980). The effects of 2- (2-pyridyl) ethylamine (PEA) in the isolated guinea-pig heart. *Proc West Pharmacol Soc* 23:41-44
7. Laher I, Triggle CR (1984). The relationship between the elevated blood pressure of the spontaneously hypertensive rat and the chemical sensitivity of smooth muscle to adrenergic agents. *Can J Physiol Pharmacol* 62:94-100
8. Laher I, Triggle CR (1984). Pharmacological studies of smooth muscle from Dahl salt-sensitive and resistant rats. *Can J Physiol Pharmacol* 62:101-104
9. Sharma JN, Fernandez PG, Laher I, Triggle CR (1984). Differential sensitivity action of Dahl salt-sensitive and Dahl salt-resistant rats to the hypotensive action of acute nifedipine administration. *Can J Physiol Pharmacol* 62:241-243
10. Laher I, Triggle CR (1984). Blood pressure, lanthanum and norepinephrine-induced mechanical response in thoracic aortic tissue. *Hypertension* 6:700-708
11. Triggle CR, Laher I (1985). Introduction and a review of changes in vascular smooth muscle functions in hypertension: isolated tissue vs. in vivo studies. *Can J Physiol Pharmacol* 63:355-365
12. Bevan JA, Bevan RD, Laher I (1985). Role of α -adrenoceptors in vascular control. *Clin Sci* 68:83s-88s
13. Laher I, Bevan JA (1985). Alpha-adrenoceptor number limits response of some rabbit arteries to norepinephrine. *J Pharmacol Exp Ther* 233:290-297
14. Laher I, Bevan JA (1985). Evidence for functional α -adrenoceptors in rabbit basilar arteries. *Euro J Pharmacol* 119:17-21
15. Laher I, Khayal MA, Bevan JA (1986). Norepinephrine sensitive, phenoxybenzamine-resistant receptor sites associated with contraction in rabbit arterial but not venous smooth muscle: possible role in adrenergic neurotransmission. *J Pharmacol Exp Ther* 237:362-368

16. Laher I, Nishimura S, Bevan JA (1986). Prazosin antagonizes norepinephrine-contractions at low-affinity, non- α -adrenoceptor sites in arterial smooth muscle. *J Pharmacol Exp Ther* 239:846-852
17. Bevan JA, Laher I, Rowan R (1987). Some implications of the high intrasynaptic norepinephrine concentrations in resistance arteries. *Blood Vessels* 24:137-140,
18. Laher I, Bevan JA (1987). Protein kinase C activation selectively augments a stretch-induced, calcium dependent tone in vascular smooth muscle. *J Pharmacol Exp Ther* 242:566-572
19. Bevan JA, Duckworth J, Laher I, Oriowo MA, McPherson GA, Bevan RD (1987). Sympathetic control of cerebral arteries: Specialization in receptor type, reserve, affinity and distribution. *FASEB J* 1:193-198
20. Laher I, Hwa JJ, Bevan JA (1998). Calcium and vascular myogenic tone. *Ann N Y Acad Sci* 522:216-225
21. Nelson MT, Laher I, Worley J (1998). Membrane potential regulates dihydropyridine inhibition of single calcium channels and contraction of rabbit mesenteric artery. *Ann N Y Acad Sci* 522:47-50
22. Laher I, van Breemen C, Bevan JA (1998). Evidence for a stretch-activated Ca^{2+} -influx pathway in myogenically active vessels. *Circ Res* 63:669-672
23. Laher I, Bevan JA (1989). Staurosporine, a protein kinase C inhibitor, attenuates Ca^{2+} -dependent stretch-induced vascular tone. *Biochem. Biophys. Res. Commun.* 158:58-62
24. Laher I, Germann P, Dowd AL, Bevan JA (1989). The selective potentiation of noradrenaline-induced tone by Bay K 8644 in rabbit basilar artery. *J Cereb Blood Flow Metabol* 9:759-764
25. Laher I, Bevan, JA (1989). Stretch of vascular smooth muscle activates tone and $^{45}Ca^{2+}$ influx. *J Hypertension* 7:517-520
26. Bevan JA, Kaminow L, Laher I, Thompson LP (1989). Pharmacology of TA-3090 (8-chloro diltiazem) related to its cerebrovascular protective properties. *Circulation* 80 (Suppl. IV): 178-183
27. Laher I, Vorkapic P, Dowd AL, Bevan JA (1989). Protein kinase C potentiates stretch-induced cerebral artery tone by increasing intracellular sensitivity to Ca^{2+} . *Biochem Biophys Res Commun* 165:312-318
28. Laher I, Thompson LP, Gagne L (1990). Protein kinase C as a modulator of response amplification in vascular smooth muscle. *Blood Vessels* 27:333-340,
29. Osol G, Laher I, Cipolla M (1991). Protein kinase C modulates basal myogenic tone in resistance arteries from the cerebral circulation. *Circ Res* 68:359-367
30. Bevan JA, Laher I (1991) Pressure and flow-dependent vascular tone. *FASEB J* 5:2267-2273
31. Germann P, Laher I, Bevan JA (1991). Platelets augment rabbit cerebral artery constriction by activating protein kinase C. *Stroke* 22:1534-1540
32. Henrion D, Laher I, Laporte R, Bevan JA (1992). Angiotensin II amplifies arterial contractile responses to norepinephrine without increasing Ca^{2+} -influx: role of protein kinase C. *J Pharmacol Exp Ther* 261:835-840
33. Henrion D, Laher I, Bevan JA (1992). Intraluminal flow increases vascular tone and $^{45}Ca^{2+}$ -influx in the rabbit facial vein. *Circ Res* 71:339-345

34. Henrion D, Laher I, Laporte R, Bevan JA (1992). Further evidence from an elastic artery that angiotensin II amplifies noradrenaline-induced contraction through activation of protein kinase C. *Eur J Pharmacol* 224:13-20
35. Henrion D, Laher I (1993). Potentiation of the norepinephrine-induced contraction by endothelin I in the rabbit aorta. *Hypertension* 27:78-83
36. Henrion D, Laher I (1993). Differential effects of staurosporine and calphostin C, two structurally unrelated inhibitors of protein kinase C on vascular tone. *Can J Physiol Pharmacol* 71:521-524.
37. Osol G, Kelley M, Laher I (1993). Myogenic tone is coupled to G protein and phospholipase C activation in small cerebral arteries. *Am J Physiol* 265:H415-H420
38. Henrion D, Laher I, Klaasen A, Bevan JA (1994). Myogenic tone in rabbit facial vein and posterior cerebral artery is influenced by small changes in extracellular sodium. *Am J Physiol* 266:H377-H383
39. Laporte R, Haeberle J, Laher I (1994). Phorbol ester-induced potentiation of myogenic tone is not associated with an increase in $^{45}\text{Ca}^{2+}$ influx in 20-kDa myosin light chain phosphorylation. *J Mol Cell Cardiol* 26:297-302
40. Henrion D, Laher I (1994). Insulin potentiates norepinephrine-induced vascular tone by activation of protein kinase C and tyrosine kinase. *Can J Physiol Pharmacol* 72:849-854
41. Laher I, Germann P, Bevan JA (1994). Neurogenically evoked cerebral artery constriction is mediated by NPY. *Can J Physiol Pharmacol* 72:1086-1088.
42. Germann P, Laher I, Poseno T, Bevan JA (1994). Barbiturate attenuation of agonist affinity in cerebral arteries correlates with anesthetic potency and lipid solubility. *Can J Physiol Pharmacol*. 72:963-969
43. van Breeman C, Chen Q, Laher I (1995). The superficial buffer barrier function of smooth muscle sarcoplasmic reticulum. *Trends Pharmacol Sci* 16:98-105
44. Laher I, Thorin-Trescases N, Ding A, Laporte R, Osol G (1995). Alpha-toxin selectively impairs endothelial-dependent vasodilator responses. *Can J Physiol Pharmacol* 73:1669-1673
45. Xie H, Laher I, Bevan JA (1996). Intracellular Ca^{2+} release in flow-induced contraction of venous smooth muscle. *Hypertension* 26:1051-1055
46. Xie H, Laher I, Bevan JA (1996). Protein kinase C modulates flow-initiated contraction. *J Pharmacol Exp Ther*. 279: 668-674
47. Henrion D, Laher I, Bevan JA (1997). Small changes in extracellular sodium influences myogenic tone in rabbit facial vein without modifying calcium influx. *Life Sci* 60: 743-749
48. Verma S, Skarsgard P, Bhanot S, Yao L, Laher I, McNeill JH (1997). Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. *Am J Hypertens* 10:1010-1019
49. Rahimian R, van Breemen C, Karkan D, Dube G, Laher I (1997). Estrogen augments cyclopiazonic acid mediated, endothelium dependent vasodilation. *Eur J Pharmacol* 327: 143-149
50. Skarsgard P, van Breemen C, Laher I (1997). Estrogen regulates myogenic tone in pressurized cerebral arteries by enhanced basal release of nitric oxide. *Am J Physiol* 273: H2248-H2256

51. Rahimian R, Laher I, Dube G, van Breemen C (1997). Estrogen and the selective estrogen receptor modulator, LY 117018 enhance the release of nitric oxide in rat aorta. *J Pharmacol Exp Ther* 283:116-122
52. Laporte R, Laher I (1997). The sarcoplasmic reticulum as a modulator of Ca²⁺ entry in vascular smooth muscle. Invited Review. *J Vasc Res* 34:325-343
53. van Breemen C, Skarsgard P, Laher I, McManus BM, Wang X (1997). Endothelium-smooth muscle interactions in blood vessels. *Clin Exp Physiol Pharmacol* 24: 989-992.
54. Verma S, Arikawa E, Yao L, Laher I, McNeill JH (1998). Insulin-induced vasodilation is dependent upon tetrahydrobiopterin synthesis. *Metabolism* 47:1037-1039
55. Lam E, Skarsgard P, Laher I (1998). Inhibition of myogenic tone by mibefridil in rat cerebral arteries. *Eur J Pharmacol* 358:165-168
56. Skarsgard P, McManus BM, van Breemen C, Laher I (1998). Endothelium-smooth muscle interaction in cardiac transplantation. *Clin Exp Pharmacol Physiol* 25:836-840
57. Skarsgard P, Wang X, McDonald P, McManus BM, van Breemen C, Laher I (2000). Profound inhibition of myogenic tone in rat cardiac allografts is due to eNOS- and iNOS- based nitric oxide, and an intrinsic defect in vascular smooth muscle contraction. *Circulation* 101:1303-1310
58. Lagaud GJL, Skarsgard PL, Laher I, van Breemen C (1999). Heterogeneity of endothelium-dependent vasodilation in pressurized cerebral and small mesenteric resistance arteries of the rat. *J Pharmacol Exp Ther* 290:832-839
59. Lagaud GJL, Lam E, Lui A, van Breemen C, Laher I (1999). Nonspecific inhibition of myogenic tone by PD 98059, a MEK 1 inhibitor, in rat middle cerebral arteries. *Biochem. Biophys. Res. Comm.* 257:523-527
60. Laporte R, Laher I (1999). Sarcoplasmic reticulum and endothelium independently regulate venous smooth muscle Ca²⁺ and contraction. *Am J Physiol* 277:H749-H755
61. Lui AH, McManus BM, Laher I (2000). Endothelial and myogenic regulation of coronary artery tone in the mouse. *Eur J Pharmacol* 410: 25-31
62. Laher I, Zhang JH (2001). Protein kinase C and cerebral vasospasm. Invited Review. *J Cereb Blood Flow Metab* 21: 887-906
63. Lagaud G, Karicehti V, Knot H, Christ GJ, Laher I (2002). Inhibitors of gap junction activity attenuate myogenic tone in cerebral arteries. *Am J Physiol.* 283:H2177-H2186
64. Liang W, Afshari K, Stothers L, Laher I (2002). The influence of ovariectomy and estrogen replacement on voiding patterns and muscarinic receptor affinity in the female rat detrusor. *Life Sciences* 71:351-362
65. Petersen HH, Choy J, Stauffer B, Afshari FM, Aalkjaer C, Leinwand L, McManus BM, Laher I (2002). Coronary artery myogenic response in a genetic model of hypertrophic cardiomyopathy. *Am J Physiol* 283:H2244-H2249
66. Lagaud G, Gaudereault N, Moore EDW, van Breemen C, Laher I (2002). Pressure dependent myogenic constriction of cerebral arteries occurs independently of voltage activation. *Am J Physiol* 283:H2187-H2195
67. Momose K, Matsuda T, Oike M, Obara K, Laher I, Suguira S, Ohata H, Nakayama K (2003). Regulatory role of mechanical stress response in cellular function:

- development of new drugs and tissue engineering. *Nippon Yakurigaku Zasshi*. 121:103-111
68. Chan H, Loughheed M, Laher I, Steinbrecher UP (2003). Oxidized LDL inhibits endothelium-dependent vasodilation by an antioxidant-sensitive lysophosphatidylcholine-independent mechanism. *J Cardiovasc Pharmacol* 41: 856-865.
 69. Moien-Afshari F, Kenyon E, Choy JC, Battistini B, McManus BM, Laher I (2003). Long-term effects of ovariectomy and estrogen replacement treatment on endothelial function. *Maturitas* 45:213-233.
 70. Moien-Afshari F, McManus BM, Laher I (2003). Immunosuppression and Transplant Vascular Disease. Invited Review. *Pharmacol Therap* 100(2): 141-156
 71. Stothers L, Laher I, Christ GT (2003). A review of the L-arginine –nitric oxide-guanylate cyclase pathway as a mediator of lower urinary tract physiology and symptoms. *Can J Urol* 10(5): 1971-1980
 72. Okon EB, Szado T, Laher I, McManus BM, van Breemen C (2003). Augmented contractile response of vascular smooth muscle in diabetic mouse model. *J Vasc Res* 43:39-47.
 73. Moien-Afshari F, Choy JC, McManus BM, Laher I (2004). Cyclosporine A treatment preserves coronary resistance artery function in rat cardiac allografts. *J Heart Lung Transplant*. 23(2): 193-203.
 74. Choy JC, Lui AH, Wei K, Yanagawa B, McManus BM, Laher I (2004). Coxsackievirus B3 infection compromises endothelial-dependent vasodilation of small coronary resistance arteries. *J Cardiovasc Pharmacol* 43:39-47.
 75. Tsang SY, Yao X, Chan FL, Wong CM, Chen ZY, Laher I, Huang Y (2004). Estrogen and tamoxifen modulate cerebrovascular tone in ovariectomized female rats. *Hypertension* 44: 78-82.
 76. Moien-Afshari F, Skarsgard PL, McManus BM, Laher I (2004). Cardiac transplantation and resistance artery myogenic tone. Invited Review. *Canadian Journal of Physiology and Pharmacology* 82: 840-848.
 77. Laporte R, Hui A, Laher I (2004). Pharmacological modulation of sarcoplasmic reticulum function in smooth muscle. Invited Review. *Pharmacological Rev* 56: 439-513.
 78. Bai N, Moien-Afshari F, Washio H, Min A, Laher I (2004). Pharmacology of the mouse isolated cerebral artery. *Vascular Pharmacology* 41: 97-106.
 79. Bai N, Lee H-C, Laher I (2005). Emerging role of cADPR in smooth muscle function. *Pharmacology and Therapeutics* 105: 189-207.
 80. Laher I, Mulvany M, Henrion D (2005). Meeting report: Highlights of the 8th International Symposium on Resistance Arteries. *Am J Physiol* 288: H1000-H1003.
 81. Nishizawa S, Laher I (2005). Signaling mechanisms in cerebral vasospasm. Invited review for *Trends in Cardiovascular Medicine* 15:24-34. Cover of journal
 82. Knot HJ, Laher I, Sobie EA, Guatimosim S, Gomez-Viquez L, Hartmann H, Song L-S., Lederer WJ, Graier WF, Malli R, Frieden M, Petersen OH (2005). 20 Years of Calcium Imaging: A Revolution in Cell Physiology to Dye For. *Molecular Interventions*. 5:112-127 Cover of journal
 83. Hunter AL, Bai N, Laher I, Granville DJ (2005). Cytochrome P₄₅₀ inhibition reduces post-ischemic vascular dysfunction. *Vasc Pharmacol*.43:213-219.

84. Wong CM, Yao X, Au CL, Tsang SY, Fung KP, Laher I, Vanhoutte PM, Huang Y (2006). Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats. *Vasc Pharmacol* 44: 290-298
85. Bai, N, Khazaei M, van Eeden SF, and Laher I (2007). The Pharmacology of Particulate Matter Air Pollution-induced Cardiovascular Dysfunction. *Pharmacology and Therapeutics* 113: 16-29
86. Leung, H-S, Yung LM, Leung, F-P, Yao, X, Chen, Z-Y, Ko WH, Laher, I, Huang, Y (2006). Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain sensitive mechanisms *Br. J. Pharmacol.* 149: 703-711.
87. Rahman MM, Elmi S, Chang TKH, Bai N, Sallam NA, Lemos VS, Moien-Afshari F, Laher I (2006). Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release. *Vasc Pharmacol* 45: 35-42.
88. Baxter KA, Laher I, Church, J, Hsiang YH (2006). Acidosis augments myogenic constriction in rat coronary arteries. *Ann Vasc Surg.*20:630-637
89. Tsang SY, Yao X, Chan HY, Chan FL, Leung C S-L, Yung LM, Au C L, Chen Z-Y, Laher I, Huang Y. (2007). Tamoxifen and estrogen attenuate enhanced vascular reactivity induced by estrogen deficiency in rat carotid arteries. *Biochem Pharmacol* 73: 1330-1339
90. Okon EB, Chung AWY, Zhang H, Laher I, van Breemen C (2007). Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes. *Can J Physiol Pharmacol* 85: 562-567
91. Leung, FP, Yung LM, Leung, HS, Au CL, Yao, X, Vanhoutte PM, Laher, I, Huang, Y (2007). Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilation *Brit J Pharmacol* 152: 223-229.
92. Rahman M, Laher I (2007). Structural and functional alteration of blood vessels caused by cigarette smoking: An overview of molecular Mechanisms. *Current Vasc Pharmacol* 5:276-292
93. Gaudreault N, Scriven DRL, Laher I and Moore EDW (2008). Subcellular characterization of glucose uptake in coronary endothelial cells. *Microvasc Res.* 75: 73-82.
94. Leung FP, Yung LM, Yao, X, Laher I, Huang Y (2007). Store-operated calcium entry in vascular smooth muscle. *Br J Pharmacol* 153: 846-857
95. Elmi S, Sallam NA, Rahman MM, Rahman, Teng X, Hunter AL, Moien-Afshari F, Khazai M, Granville DJ, Laher I (2008). Sulfaphenazole treatment restores endothelium-dependent vasodilatation in diabetic mice. *Vasc. Pharmacol.* 48: 1-8
96. Khazaei M, Moien-Afshari F, Rahman MM, Kieffer T, Laher I (2007). Effect of exercise on augmented aortic vasoconstriction in the db/db mouse model of type-II diabetes. *Physiol Res* 57:847-856
97. Leung FP, Yung LM, Laher I, Yao X, Chen ZY, Huang Y (2008). Exercise, vascular wall and cardiovascular diseases: An update (Part 1) *Sports Medicine* 1009-1024.
98. Leung FP, Yung LM, Laher I, Yao X, Chen ZY, Huang Y (2009). Exercise, vascular wall and cardiovascular diseases: An update (Part 2) *Sports Medicine* 39: 45-63.
99. Khazaei M, Moien-Afshari F, Laher I (2007). Vascular endothelial function in health and diseases. *Pathophysiology* 15: 49-67.
100. Liang W, Tan CY, Ang L, Granville DJ, Wright JM, Laher I (2008). Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice. *J Physiol Sci.* 58: 405-411

101. Moein-Afshari F, Ghosh S, Khazai M, Keiffer T, Brownsey RW, Laher I (2008). Exercise restores endothelial function independent of weight loss, hyperglycemic status or lipid profile in db/db mice. *Diabetologia* 51: 1327-1337.
102. Moein-Afshari F, Khazai M, Ghosh S, Elmi S, Rahman M, Sallam N, Laher I (2008). Exercise restores coronary vascular function independent of myogenic tone or hyperglycemic status in db/db mice. *Am J Physiol* 295: H1470-H1480.
103. Bloom SR, Kuhajda FP, Laher I, Pi-Sunyer FX, Ronnett G, Tan TMM, Weigle DS (2008). The Obesity Epidemic: Pharmacological Challenges. *Molecular Interventions* 8: 80-97. *Cover of journal*.
104. Tamagawa E, Bai N; Morimoto K; Gray C; Mui, T, Yatera K, Zhang X; Xing L, Li Y, Laher I, Sin D; Man S.F.P; van Eeden, S (2008). Particulate matter induced lung inflammation causes endothelial dysfunction: molecular links *Am J Physiol* 295:L79-L85.
105. Marchant D, Dou Y, Luo H, McDonough JE, Si X, Walker E, Luo Z, Tehrani A; Arner A, Hegele RG, Laher I, McManus BM (2009). Bosentan Improves Cardiac Function while Enhancing Viral Load via p38 MAP Kinase Activation during Coxsackievirus-Induced Myocarditis. *Circ Res* 104: 613-621
106. Ghosh S, Khazaei M, Moein-Afshari F, Ang LS, Granville DJ, Verchere CB, Dunn SR, McCue P, A. Mizisin, Sharma, K. Laher I. (2008). Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. *Am J Physiol Renal Physiol* 296: F700-F708
107. Hill MA, Meininger DA, Davis MJ and Laher I (2009). Therapeutic potential of pharmacologically targeting arteriolar myogenic tone. *Trends in Pharmacological Sciences* 30: 363-374.
108. Zhang R, Bai N, So J, Laher I, MacLeod KM, Rodrigues R (2009). The ischemic metabolite lysophosphatidylcholine increases rat coronary arterial tone by endothelial-dependent mechanisms. *J Mol Cell Cardiol* 47: 112-120.
109. Khazaei M, Sharifi AM, Golbidi S, Laher I (2009). Reduction in risk of myocardial infarction, stroke, and death from cardiovascular causes. Focus on ramipril. *Clinical Medicine: Therapeutics* 1: 911-925.
110. Golbidi S, Laher I (2010). Anti-oxidant therapies in human endocrine disorders. *Free Radical Biology and Medicine* 16: RA9-24.
111. Ghosh S, Golbidi S, Werner I, Verchere CB, Laher I (2010). Selecting exercise regimens and strains to modify obesity and diabetes in rodents: An Overview. *Clinical Science* 119: 57-74.
112. Vadhavkar M, Sea J, Golbidi S, Longpere M, Laher I, Stothers L (2011). Exercise improves bladder function in diabetic mice. *NeuroUrol Urodyn* 30: 174-182.
113. Salam N, Khazaei M, Laher I (2010). Effect of moderate-intensity exercise on plasma C-reactive protein and aortic endothelial function in type 2 diabetic mice *Mediators Inflamm* 2010: Article ID 149678, 7 pages (doi:10.1155/2010/149678).
114. Alan N, Ramer LM, Inskip JA, Golbidi S, Ramer M, Laher I, Krassioukov AV (2010). Recurrent autonomic dysreflexia exacerbates vascular dysfunction following spinal cord injury. *Spine J.* 10: 1108-1117.
115. Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, Golbidi S, Churg AM (2011). Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. *Am J Resp Crit Care Med* 183: 50-58.

116. Golbidi S, Laher I (2010). Lower urinary tract dysfunction in diabetes mellitus. *Front Pharmacol Urogenital Disorders*;doi:10.3389/fpahar.2010.00136
117. Golbidi S, Laher I (2011). Molecular mechanisms in exercise induced cardioprotection. *Cardiol Res Pract Volume 2011 (2011), Article ID 972807, 15 pages.*
118. Sallam N, Fisher A, Golbidi S, Laher I (2011). Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice *Naunyn-Schmiedeberg's Archives of Pharmacology* 5: 483-492.
119. Golbidi S, Laher I (2011). Antioxidants in the treatment of diabetes. *Curr Diabetes Rev* 7: 106-125.
120. Laher I (2011). Microparticles have macro-effects in sepsis. *Editorial. Critical Care Medicine* 39: 1842-1843.
121. Golbidi S, Badran M, Laher I (2011). Antioxidants and anti-inflammatory effects of exercise in diabetic patients. *Experimental Diabetes Research* 2012: Article ID 941868, 16 pages.
122. Badran M, Laher I (2011). Obesity in Arabic-speaking countries. *J. Obesity vol. 2011, Article ID 686430, 9 pages, 2011. doi:10.1155/2011/686430.*
123. Laher I (2011). Clots and blots: a stroke of good fortune in identifying protein changes in cerebral accidents. *CNS Neuroscience Therapeutics (In Press).*
124. Golbidi S, Badran M, Laher I (2011). Diabetes and alpha lipoic acid. *Frontiers in Ethnopharmacology* 2: Article 69: 1-15
125. Chan, Y-C, Leung FP, Tian XY, Yung LM, Lau CW, Chen ZY, Yao X, Laher I, Huang Y (2012). Raloxifene improves vascular reactivity in pressurized septal coronary arteries of ovariectomized hamsters fed cholesterol diet. *Pharmacological Research* 65: 182-188.
126. Golbidi S, Badran M, Ayas N, Laher I (2011). Cardiovascular consequences of sleep apnea. *Lung* 190: 113-132.
127. West CR, Al Yahya A, Laher I, Krassioukov A (2013). Peripheral vascular function in spinal cord injury: A systematic review. *Spinal Cord* 51: 10-19
128. Chen AF, Chen D, Daiber A, Faraci FM, Li H, Rembold CM, Laher I (2012). Free radical biology of the cardiovascular system. *Clinical Science* 123: 73-91.
129. Andriantsitohaina R, Duluc L, Garcia-Rodriguez JC, Valle LC, Guevara –Garcia M, Simard G, Su DF, Velasquez-Perez L, Wilson JX, Laher I (2012). Systems biology of antioxidants. *Clinical Science* 123: 173-192.
130. Kauffenstein G, Laher I, Matrougui K, Guerineau NC, Henrion D (2012). Emerging role of G protein-coupled in microvascular myogenic tone. *Cardiovascular Research* 95: 223-232.
131. Golbidi S, Laher I (2012) Exercise and the cardiovascular system. *Cardiology Research and Practice* 2012: 210852 (PMID 22701195).
132. Golbidi S, Mesdaghinia A, Laher I (2012). Exercise in the metabolic syndrome. *Oxidative Medicine and Cellular Longevity, Volume 2012 (2012) Article ID 349710, 13 pages, doi 1155/2012/ 349710.*
133. Badran M, Laher I (2012). Type II Diabetes mellitus in Arabic-speaking countries. *International Journal of Endocrinology vol. 2012, Article ID 902873, 11 pages, 2012. doi:10.1155/2012/902873.*
134. Andriantsitohaina R, Auger C, Chataigneau T, Etienne-Selloum N, Li H, Martinez MC, Schini-Kerth VB, Laher I (2012). Molecular mechanisms of the cardiovascular protective effects of polyphenols. *Brit J Nutr* 108: 1532-1549.

135. Petersen KK, Hoerlyck A, Ostergaard KH, Andresen J, Broegger T, Skovgaard N, Telinius N, Laher I, Bertelsen MF, Grondahl C, Smerup M, Secher NH, Brondum E, Hasenkam M, Wang T, Baandrup U, Aalkjaer C (2013). Protection against high intravascular pressure in the leg of giraffes. *Am J Physiol Regul Integr Comp Physiol* 305: R1021-R1030.
136. Laher I, Beam J, Botta A, Barendregt R, Sulistyoningrum D, Devlin A, Rheault M, Ghosh S (2013). Short-term exercise worsens cardiac oxidative stress and fibrosis in 8-month old *db/db* mice by depleting cardiac glutathione. *Free Radical Research* 47: 44-54.
137. Chang A, Patenaude A, Lu K, Fuller M, Ly M, Kyle A, Golbidi S, Wang Y, Walley K, Minchinton A, Laher I, Karsen A (2013). Notch-dependent regulation of the ischemic vasodilatory response. *Arteriosclerosis, Thrombosis and Vascular Biology* 33: 510-512.
138. Botta A, Laher I, Beam J, DeCoffee D, Brown K, , Halder S, Devlin A, Gibson D, Ghosh S (2013). Short-term exercise induces PGC-1 α , ameliorates inflammation and increases mitochondrial membrane proteins but fails to increase respiratory enzymes in aging diabetic hearts. *PLoS ONE* 8(8): e70248. doi:10.1371/journal.pone.0070248
139. Golbidi S, Laher I (2013). Potential mechanisms of exercise in gestational diabetes. *J. Nutrition and Metab.* vol. 2013, Article ID 285948, 16 pages, 2013. doi:10.1155/2013/285948.
140. Golbidi S, Laher I (2013). Exercise and the aging endothelium. *J. Diabetes Res.* vol. 2013, Article ID 789607, 12 pages, 2013. doi:10.1155/2013/789607.
141. Golbidi S, Laher I (2014). Exercise induced adipokine changes and the metabolic syndrome. *J. Diabetes Res.* vol. 2014, Article ID 726861, 16 pages, 2014. doi:10.1155 /2014 /726861.
142. Badran, M, Golbidi, S, Devlin, A, Ayas, N, Laher, I (2014). Chronic intermittent hypoxia causes endothelial dysfunction in a mouse model of diet-induced obesity. *Sleep Medicine* 15: 596-602.
143. Asgary S, Keshvari M, Afshani MR, Amiri M, Laher I, Haghjoojavanmard S (2014). A randomized controlled clinical trial of fresh orange juice intake on physiological characteristics in healthy volunteers. *ISRN Nutrition*, vol. 2014, Article ID 405867, 7 pages, 2014. doi: 10.1155/2014/405867.
144. Badran M, Ayas N, Laher I (2014). Insights into obstructive sleep apnea research. *Sleep Medicine pii: S1389-9457(14)00047-1.* doi: 10.1016/j.sleep.2014.01.009 .
145. Badran, M, Ayas, N, Laher, I (2014). Cardiovascular Complications of Sleep Apnea: Role of Oxidative Stress. *Oxid Med Cell Longev.* 2014;2014:985258.
146. Laher I (2014). Diabetes and the Arab nations: have we reached a tipping point and how do we silence the alarm? *IEEE Engineering in Medicine and Biology Society (IEEE EMBS). Special Issue on Diabetes* 5: 26-29.
147. Golbidi S, Botta A, Gottfred S, Nusrat A, Laher I, Ghosh S (2014). Glutathione administration reduces mitochondrial damage and shifts cell death from necrosis to apoptosis in aging diabetic mice hearts during exercise. *Br J Pharmacol (In Press, 2014).*
148. Ayas NT, Hirsch Allen AJ, Laher I, Bradley TD, Malhotra A, Polotsky VY, Tasali E (2014). New frontiers in obstructive sleep apnea. *Clinical Science* 127: 209-216.
149. Aleliunas RE, Olson JD, Aljaad A, Glier MB, Laher I, Green T, Devlin AM (2014). Programming of adiposity by gestational exposure to folic acid and vitamin B12 imbalance. *Can J Diabetes Suppl* 2:S289. doi: 10.1016/j.jcjd.2013.03.352.

2. BOOK

1. "Systems Biology of Oxidative Stress: Free Radicals and Anti-oxidants Biology). *Handbook of Pharmacology* Edited by Ismail Laher. Published by Springer-Verlag. Five volumes and 182 chapters. (Due April 2014)
2. 'Nutritional Antioxidant Therapies: Treatments and Perspectives' Edited by Kais Algubory and Ismail Laher. Published by Springer-Verlag. (Due September 2016)

3. NON-REFEREED PUBLICATIONS

Abstracts

1. Laher I, Riedel, BE, McNeill JH: Effects of histamine (HIS) on isolated cardiac preparations of the rat and kitten. Presented at 23rd Annual Meeting of the Canadian Federation of Biological Societies, St. John's, NFD, June 1980.
2. Laher I, Triggle CR: Effect of cocaine on noradrenaline (NA) response of vascular smooth muscle (VSM) and nonvascular smooth muscle (non VSM) from spontaneously hypertensive rats (SHR). Presented at Joint ASPET/PSC meeting, Calgary, AB, August 1981.
3. MacLeod KM, Siegle PKS, Laher I, McNeill JH: Beta-adrenoceptor alterations in hyperthyroid guinea-pig left atria. Presented at Joint ASPET/PSC meeting, Calgary, AB, August 1981.
4. Triggle CR, Laher I : Uptake₁ and noradrenergic (NA) sensitivity of smooth muscle from spontaneous hypertensive rats (SHR) and genetically related animals. Presented at 24th Annual Meeting of the Canadian Federation of Biological Societies, Montreal, PQ, June 1981.
5. Triggle CR, Laher I: The relationship between the neuronal uptake of norepinephrine (NE), postsynaptic adrenergic sensitivity of smooth muscle (SM) and blood pressure in genetically hypertensive rats (SHR). Presented at the Annual Meeting of Canadian Cardiovascular Society, Montreal, PQ October 1981.
6. Triggle CR, Laher I: The relationship between the neuronal uptake of norepinephrine (NE), postsynaptic adrenergic sensitivity of smooth muscle (SM) and the mean blood pressure (MBP) of genetically hypertensive rats. Presented at the Federation of American Societies for Experimental Biology, New Orleans, LA, April 1982.
7. Laher I, Triggle CR: Role of the sympathetic nervous system (SNS) in regulating the adrenergic sensitivity of smooth muscle from genetically hypertensive rats. Presented at 25th Annual Meeting of the Canadian Federation of Biological Societies, Edmonton, AB June 1982.

8. Laher I, Triggle CR: The relationship between blood pressure and the mechanical response to lanthanum. Presented at the Federation of American Societies for Experimental Biology, Chicago, IL, April 1983.
9. Fernandez PJ, Sharma JN, Kim BK, Triggle CR, Idikio H, Laher I: Left ventricular regression and blood pressure control in the Dahl (D) rat with MK-421 (an angiotensin I converting enzyme inhibitor, CEI) and hydrochlorothiazide (HTZ). Presented at 12th Annual Meeting of the American College of Clinical Pharmacology, Washington, DC April 1983
10. Sharma JN, Fernandez PG, Kim BK, Triggle CR, Idikio H, Laher I. Blood pressure control and hypertensive heart changes in the Dahl (D) rat: MK-421 (an angiotensin I converting enzyme inhibitor, CEI) versus hydrochlorothiazide (HTZ). Presented at 12th Annual Meeting of the American College of Clinical Pharmacology, Washington, DC April 1983.
11. Triggle CR, Laher I: Changes in vascular smooth muscle (VSM) function: Isolated tissue versus in vivo studies. Presented at 26th Annual Meeting of the Canadian Federation of Biological Sciences, Saskatoon SK, June 1984.
12. Laher I, Bevan JA: Alpha-adrenoceptor number limits contraction in some rabbit arteries. Presented at Federation of American Societies of Experimental Biology, Anaheim, CA, April 1985.
13. Laher I, Bevan JA: Presence of phenoxybenzamine-resistant sites for norepinephrine in large arteries: a generalized phenomenon? Invited Speaker at Satellite Symposium on Smooth Muscle Function. XXX International Union of Physiological Sciences, Banff, AB, July 1986.
14. Laher I, Bevan JA: Phenoxybenzamine (PBZ) resistant, high threshold site for noradrenaline (NA) contraction of arteries. Presented at symposium of XXX International Union of Physiological Sciences. Satellite Symposium on Smooth Muscle Function, Banff, AB, July 1986.
15. Bevan JA, Laher I, Oriowo MA, Yang J, Bevan RD: The contribution of changes in receptor number and affinity to variation in vascular responsiveness to noradrenaline. Presented at British Pharmacology Society Meeting, Bath, England, April 1986.
16. Laher I, Bevan JA: Calcium-dependent myogenic tone is augmented selectively by phorbol esters. Presented at Federation of American Societies of Experimental Biology, Washington, DC, March 1986.
17. Bevan JA, Laher I, Oriowo MA, Yang J, Bevan RD: Contribution of changes in receptor number and affinity to variation in vascular responsiveness to norepinephrine. Presented at the Springfield Blood Vessel Symposium, Springfield, IL, April 1986.
18. Bevan JA, Laher I, Hwa JJ: Calcium and vascular myogenic tone: Presented at International Symposium on Calcium Antagonists, New York Academy of Sciences, February 1987.
19. Laher I, Bevan JA. Calcium-channel activation by Bay K 8644 augments both myogenic tone and $^{45}\text{Ca}^{2+}$ -influx. Presented at the Vascular Neuroeffector Mechanisms, Melbourne, Australia, September 1987.
20. Laher I, van Breemen C, Bevan JA: Calcium entry during stretch-induced vascular tone. Presented at Calcium Antagonists in Hypertension, Basel, Switzerland, February 1988.

21. Laher I, Hwa JJ, Bevan JA: Ionic selectivity of stretch-activated Ca²⁺ influx pathways in vascular smooth muscle. Presented at Federation of Societies for Experimental Biology Smooth Muscle Conference, Stowe, VT, June 1988.
22. Laher I, Bevan JA: Stretch of vascular smooth muscle activates tone and ⁴⁵Ca²⁺-influx. Presented at Myogenic Mechanisms in the Control of Systemic Resistance, Funchal, Madeira, March 1989.
23. Germann P, Laher I, Bevan J: Pentobarbital reduces the affinity of histamine for its receptors in rabbit brain arteries. Presented at Federation of Societies for Experimental Biology at Washington, DC April 1990.
24. Osol G, Laher I, Cipolla M, Knutson S: Protein kinase C (PKC) modulates myogenic tone in resistance arteries of the cerebral circulation. Presented at 13th Scientific Meeting of the International Society of Hypertension at Montreal, PQ, June 1990.
25. Laher I, Osol G: Stretch and pressure activation of vascular myogenic tone is modulated by protein kinase C. Presented at 6th International Symposium on Cellular Endocrinology, Lake Placid, NY, August 1990.
26. Osol G, Laher I, Cipolla M: Effects of protein kinase C inhibition on basal myogenic tone in small cerebral arteries. Presented at the American Heart Association, 63rd Annual Meeting, Dallas, TX, November 1990.
27. Germann P, Laher I, Bevan JA: Barbiturate attenuation of agonist affinity in cerebral arteries correlates with lipid solubilities. Presented at American Society of Anesthesiologists Annual Meeting, October 1990.
28. Germann P, Laher I, Bevan JA: NPY antibody selectively inhibits sympathetic vasoconstriction of the rabbit basilar artery. Presented at Federation of Societies for Experimental Biology at Atlanta, GA, April 1991.
29. Henrion D, Laher I, Bevan JA: The increase in wall force associated with stretch requires a different calcium-dependent mechanism than intraluminal flow. Presented at American Heart Association meeting at Anaheim, CA, November 1991, *Circulation* 84 (4; Suppl): II-718, 1991.
30. Henrion D, Laporte R, Laher I, Bevan JA: Angiotensin II potentiates norepinephrine and caffeine-induced contraction by activation of protein kinase C. Presented at American Heart Association meeting at Anaheim, CA, November, 1991, *Circulation* 84 (4;Suppl):II-625, 1991.
31. Henrion D, Laher I, Bevan JA: Flow-induced contraction is associated with an increased ⁴⁵Calcium-influx in the rabbit facial vein. Presented at the American Heart Association Meeting at Chicago, IL, *Hypertension* 18:400, 1992.
32. Laporte R, Henrion D, Laher I, Bevan JA: Complex relationship between stretch-induced wall force and free intracytoplasmic concentration in the rabbit facial vein. Presented at Federation of Societies for Experimental Biology, Anaheim, CA, April 1992.
33. Osol G, Laher I, Kelley M: Myogenic tone is coupled to G protein and phospholipase C (PLC) activation in small cerebral arteries. Presented at Experimental Biology, New Orleans, LA, April, 1993.
34. Laher I, Germann PG, Bevan J: Protein kinase C modulates increased cerebrovascular reactivity caused by activated platelets. Presented at Vth International Conference on Cerebral Vasospasm, Edmonton, AB, May 1993.
35. Vijayakumar E, Laher I, Ryan LD, Bevan RD, Bevan JA: Can maternal magnesium (Mg) and nifedipine (NIF) therapy inhibit umbilical vessel contractility and

- exacerbate bleeding in the neonate? Presented at the American Pediatric Society and The Society for Pediatric Research Conference, Washington, DC, May 1993.
36. Laher I, Henrion D: The sarcoplasmic reticulum buffers calcium in vascular smooth muscle. Presented at the Gordon Research Conference on Calcium Signalling, Henniker, NH, June 1993.
 37. Osol G, Laher I, Kelley M: Tyrosine kinase activation by transmural pressure may play a role in cerebral artery myogenic tone. Presented at the American Heart Association 19th International Joint Conference on Stroke and Cerebral Circulation, February 1994.
 38. Laher I, Henrion D, Laporte R: The sarcoplasmic reticulum buffers calcium entry due to depolarization of vascular smooth muscle. Presented at the Fourth International Symposium on Resistance Arteries, Stowe, VT, January 1994. *J. Vasc. Res.* 31(Suppl. 1): 425, 1994.
 39. Laporte R, Ding AX, Laher I, Bevan JA: Modulation of Ca²⁺-induced vasoconstriction by the sarcoplasmic reticulum. Presented at Experimental Biology Anaheim, CA, April 1994.
 40. Henrion D, Laher I, Bevan JA: Stretch-induced vascular myogenic tone is associated with ²²Na⁺ uptake. Presented at VIIIth International Symposium on Vascular Neuroeffector Mechanisms, Kananaskis Village, AB, August 1994.
 41. Laher I, Laporte R: The sarcoplasmic reticulum buffers Ca²⁺-activation of vascular tone. Presented at the FASEB Summer Research Conference on Smooth Muscle, Copper Mountain, CO, June 1994.
 42. Henrion D, Laher I, Bevan JA: Stretch-induced myogenic tone in the rabbit facial vein is correlated with ²²Na⁺ uptake. Presented at VIIIth International Symposium on Vascular Neuroeffector Mechanisms, Kananaskis Village, AB, August 1994.
 43. Laher I, Thorin-Trescases N, Ding A, Laporte R, Osol G: Alpha-toxin selectively impairs endothelial-dependent vasodilator responses. Presented at Experimental Biology, Atlanta, GA, April 1995.
 44. Laporte R, Li C, Haeberle JR, Laher I: The sarcoplasmic reticulum prevents myosin light chain phosphorylation and subsequent tone production in vascular smooth muscle by acting as a storage barrier for Ca²⁺ influx. Presented at Experimental Biology, Atlanta, GA, April 1995.
 45. Laher I, Thorin-Trescases N, Ding A, Laporte R, Osol G: Alpha-toxin eliminates endothelial-dependent vasodilation. Presented at Microcirculation Society, Atlanta, GA, April 1995.
 46. Laporte R, Laher I: The sarcoplasmic reticulum modulates vascular myogenic tone by buffering Ca²⁺-entry. Presented at Microcirculation Society, Atlanta, GA, April 1995.
 47. Xie H, Laher I, Bevan JA: Flow-induced vasoconstriction is modulated by calcium release and protein kinase C (PKC) activation. Presented at Inter-American Society of Hypertension, Montreal, PQ, June 1995.
 48. Rahimian R, van Breemen C, Ruscko J, Li L, Bolzen B, Dube G, Laher I: Greater stimulated and basal release of nitric oxide in the presence of estradiol. Presented at Experimental Biology, Washington, DC, April 1996.
 49. Skarsgard PL, Laher I, van Breemen C: Estrogen regulates myogenic tone in pressurized cerebral arteries by enhanced release of EDRF. Presented to the Canadian Association of General Surgeons Meeting, Mississauga, ON, June 1996.

50. Rahimian R, Laher I, van Breemen C: Estrogen augments cyclopiazonic acid mediated endothelium dependent asodilation. Presented at the Signal Transduction in the Endothelium Symposium, Vancouver, BC, September 1996.
51. Rahimian R, Dube G, Laher I, van Breemen C: 17- β -Estradiol increases basal release of nitric oxide in rat aorta. Presented at the IXth International Vascular Biology Meeting, Seattle, WA, September 1996.
52. Skarsgard PL, Laher I, van Breemen C: Estrogen regulates myogenic tone in cerebral arteries by enhanced release of EDRF. Presented at the Signal Transduction in the Endothelium Symposium, Vancouver, BC, September 1996.
53. Verma S, Yao L, Laher I, McNeill JH: Effects of insulin on reactivity of arteries to angiotensin-II in insulin resistant and hypertensive rats. Presented at the meeting on Angiotensin Receptor Blockade Symposium, Winnipeg, MN, October 1996.
54. Rahimian R, Laher I, Dube G, van Breemen C: Estrogen augments cyclopiazonic acid mediated endothelium-dependent vasodilation. Presented at Experimental Biology, New Orleans, LA, April 1997.
55. Verma S, Bhanot S, Laher I, Yao L, McNeill JH: Sympathetic nervous system (SNS) and the vascular effects of insulin. Presented at the International Society for Heart Research, XIX Annual Meeting, Vancouver, BC, July 1997.
56. Yao L, Tam S, Verma S, Laher I, McNeill JH: Bis(maltoato)oxovanadium(IV) (BMOV) restores vascular reactivity in STZ-diabetic rats. Presented at the International Society for Heart Research, XIX Annual Meeting, Vancouver, BC, July 1997.
57. McNeill JH, Verma S, Erikawa E, Bhanot S, Laher I, Yao L: Insulin -induced vasodilation is dependent upon tetrahydrobiopterin synthesis. Presented at the 41st. annual meeting of the Western Pharmacological Society, Mazatlan, Mexico, January 1998.
58. Arikawa E, Verma S, Yao L, Laher I, McNeill JH: Inhibition of tetrahydrobiopterin synthesis decreases insulin-mediated vasodilation. Presented at the Canadian Diabetes Association Meeting, Calgary, AB, August 1998.
59. Lam E, Lagaud GJL, Lui A, Laher I: Nonspecific inhibition of vascular tone by the MEK1 inhibitor, PD98059, in pressurized rat cerebral arteries. Presented at Experimental Biology, Washington, DC, April 1999.
60. Rahimian R, Wang X, Laher I, van Breemen C: Gender differences in the basal intracellular Ca²⁺ concentration in the rat valvular endothelial cell. Presented at Experimental Biology, Washington, DC, April 1999.
61. Lagaud GJL, Chan S, Laher I, van Breemen C, Dube G: Comparative vascular functions of resistance and conduit arteries in type II diabetic and wild type mice. Presented at Experimental Biology, Washington, DC, April 1999.
62. van Breemen C, Szado T, Nazer M, Lee CH, Lam E, Lagaud G, Laher I: SR regulation of Ca entry and vascular smooth muscle tone. Presented at the Fourth US-Japan Workshop on Molecular and Cellular Aspects of Vascular Smooth Muscle Function, Hawaii, May 1999.
63. Rahimian R, Wang X, Laher I, Dube G, van Breemen C: Gender difference in the basal nitric oxide release and intracellular Ca concentrations in rat valvular endothelial cells. Presented at the Canadian Society for Clinical Investigation, Western Regional Meeting, Vancouver, BC, June 1999. *J Clin Invest Med* 22:222, 1999.

64. Knot H, Laher I: Potassium channels regulate renal vascular tone in response to elevated extracellular potassium. Presented at Experimental Biology, San Diego, CA, April 2000.
65. Lagaud GJL, Laher I, van Breemen C: Rat cerebral and mesenteric resistance arteries have different signaling pathways for myogenic tone. Presented at the XIth International Vascular Biology Meeting, Geneva, Switzerland, September 5-9, 2000.
66. Liang W, Afshar K, Stothers L, Laher I: Gender Differences in receptors controlling the Lower Urinary Tract of Wistar Rats. Northwest Urologic Association Meeting. Seattle, WA, December 2, 2000). *Winner of the Tate Mason Award for Best Research.*
67. Liang W, Laher I, Stothers L, Afshar K: Menopausal influences on continence and muscarinic receptor affinity in the female rat detrusor muscle. Presented at the Joint meeting of the Australasian, British, Canadian and Western Pharmacological Societies. Vancouver, BC, March, 2001.
68. Kuang X, Wang X, Liang W, Laher I, van Breemen C: The roles of CTX and Apamin sensitive K_{ca} currents in endothelial cell hyperpolarization and endothelium-dependent relaxation in rabbit aorta. Presented at the International Symposium on Cell Signaling-From Diseases to Drug Discovery. The Chinese University of Hong Kong, Hong Kong, October 2001.
69. Moien Afshari F, Choy J, McManus BM, Laher I: Long-term estrogen loss and endothelial regulation of arterial tone. Presented at the 14th International Congress of Geographic Medicine and 15th Iranian Congress of Physiology and Pharmacology, Shiraz, Iran, November 2001.
70. Moien Afshari F, McManus BM, Laher I: Cyclosporine immunosuppression may improve myogenic tone of coronary arteries in rat transplant vascular disease. Presented at the 14th International Congress of Geographic Medicine and 15th Iranian Congress of Physiology and Pharmacology, Shiraz, Iran, November 2001.
71. Moien Afshari F, McManus BM, Laher I: Coronary artery dysfunction in transplant vascular disease is reversed by cyclosporine treatment. "Frontiers In Cardiovascular Research Symposium "at the Hope Heart Institute, Seattle, WA, October 2001.
72. Lui A, Choy JC, Wei K, Yanagawa B, McManus BM, Laher I: Cardiac vascular dysfunction in coxsachievirus B3-Infection. "Frontiers In Cardiovascular Research Symposium "at the Hope Heart Institute, Seattle, WA, October 2001.
73. Moien-Afshari F, Lagaud G, Gaudreault N, Moore EDW, Christ G, Laher I: Lipid mediators in vascular myogenic tone. Symposium on Vascular Myogenic Tone at Congress Symposium of the 75th Annual Meeting of the Japanese Pharmacological Society, Kumamoto, Japan, March 2002.
74. Chan LLY, Laher I, Kuang A, Liang W, van Breemen C, Wang X: The roles of CTX and Apamin-sensitive K_{ca} currents in endothelial cell hyperpolarization and endothelium-dependent relaxation in rabbit aorta. XIVth World Congress of Pharmacology, IUPHAR, San Francisco, CA, July 7-12, 2002.
75. Laher I, Lagaud G, van Breemen C: Ca²⁺-sensitization during myogenic activation of rat cerebral arteries. Myogenic Centennial 2002 Conference, Stowe, VT, June 12-15, 2002.

76. Petersen H, McManus BM, Leinwand L, Laher I, Aalkjaer C: Reduced coronary myogenic tone in a mouse model of hypertrophic cardiomyopathy. . Myogenic Centennial 2002 Conference, Stowe, VT, June 12-15, 2002.
77. Chan L, Laher I, Kuang XY, Liang W, van Breemen C, Wang X. The roles of CTX and Apamin-sensitive K_{Ca} currents in endothelial cell hyperpolarization and endothelium-dependent relaxation in rabbit aorta. 10th International Symposium Vascular Neuroeffector Mechanisms, Lake Tahoe, CA, July 12-15, 2002.
78. Lee S, MacDonald PS, Devine D, Serrano K, Hsiang YN, Laher I: Is activated complement a modulator of l-arginine metabolism for the formation of nitric oxide? 13th Annual Meeting of Society for Vascular Medicine and Biology, Boston, MA, June 6-8, 2002.
79. Knot HJ, Lagaud G, Karicheti V, van Breemen C, Christ GJ, Laher I: Inhibitors of gap junctions attenuate myogenic tone in cerebral arteries. . Myogenic Centennial 2002 Conference, Stowe, VT, June 12-15, 2002.
80. Baxter KA, Laher I, Church J, Hsiang YN: The Effect of Acidosis on Rat Coronary Artery Tone. Presented to the Society of Vascular Surgeons Meeting, Toronto, ON, June 8, 2003.
81. Gaudreault N, Blanche T, Laher I, Scriven DRL, Moore EDW: Characterisation of glucose transport in endothelial cells of small contractile arteries. Presented to the 18th International Diabetes Federation Congress, Paris, France, August 24-29, 2003.
82. Moien-Afshari F, Choy JC, McManus BM, Laher I: Cyclosporine A Treatment Preserves Coronary Artery Function in Rat Cardiac Allografts. Presented to the 16th Iranian Congress of Physiology and Pharmacology, Tehran, Iran, May 9-13, 2003.
83. Laher I: Myogenic and endothelial dysfunction in inflammatory heart disease. Invited Speaker at Symposium on "Inflammatory Heart Diseases and Cardiac Failure" at 46th Annual Meeting of the Canadian Federation of Biological Societies, Ottawa, ON, June 11-15, 2003.
84. Laher I, Christ G, Knot H: Gap junctions modulate resistance artery myogenic tone. FASEB Summer Research Conference on Smooth Muscle, Snowmass, CO July 5-10, 2003.
85. van Eeden SF, Holman C, Yatera, K, Vincent R, and Laher I (2004) Exposure to atmospheric air pollution particles induces endothelial dysfunction. *Am.J. Respir.Crit. Care Med*: 169: A885 The American Thoracic Society 100th International Conference. Orlando, Florida, USA. 21-26 May 2004.
86. Bai N, Hunter AL, Laher I and Granville DJ (2004). Sulfaphenazole reduces post-ischemic vascular dysfunction. The 2004 International Society for Heart Research World Congress: Cardiology bench to bedside. The Science and The Practice. Brisbane, Australia. August 2004.
87. Laher I, Christ G and Knot H (2004). Inhibitors of gap junctions attenuate myogenic tone in cerebral arteries and reveal Ca^{2+} signaling modalities. *Experimental Biology*, Washington, DC. April 2004.
88. Bai N, Moien-Afshari F, Washio H, Min A and Laher I (2004). The physiological and pharmacological characteristics of the mouse isolated cerebral artery. The 8th International Symposium on Resistance Arteries, Angers, France. June 2004.
89. Moien-Afshari F, Choy JC, McManus BM, and Laher I (2004). Coronary resistance artery dysfunction in rat cardiac allograft is reversed by cyclosporine A treatment.

- The 8th International Symposium on Resistance Arteries, Angers, France. June 2004.
90. Bai N, Hunter AL, Granville DJ and Laher I (2004). Sulfaphenazole reduces post-ischemic vascular dysfunction. The 8th International Symposium on Resistance Arteries, Angers, France. June 2004.
 91. Chan YC, Yao X, Liu C, Laher I, Vanhoutte PM and Huang Y (2004). Involvement of endothelium in raloxifene-induced vasodilation in pressurized mesenteric artery. *Experimental Biology*, Washington, DC. April 2004.
 92. Moazed B, Tang, G, Liu P, Moien-Afshari F, Washio H, Laher I, Triggle CR, McNeill JR, Wang R, Gopalakrishnan V. (2004). Des-acyl Ghrelin and Ghrelin Evoke Potent Vasodilatation in the Rat mesenteric Vascular Bed: Selective Activation of K_{Ca} Channels on Endothelial Cells. The 8th International Symposium on Resistance Arteries, Angers, France. June 2004.
 93. Khazaei M, Moien- Afshari F, Merchant S, Laher I (2005). Exercise improves endothelial dysfunction in db/db mice model of type II diabetes. *Experimental Biology 2005*. San Diego, CA, USA. April 2005.
 94. Khazaei M, Moien- Afshari F, Merchant S, Laher I (2005). Exercise improves diabetes-related endothelial dysfunction in db/db mouse model of type II diabetes. The 2005 Annual Conference of the Canadian Society for Clinical Pharmacology. Vancouver, BC, Canada April 2005.
 95. Hunter AL, Bai N, McManus BM, Laher I, Granville DJ. (2005) Inhibition of Cytochrome p450 2C. Restores Vascular Function Following Global Ischemia and Reperfusion. Canadian Cardiovascular Congress 2005, Montreal QC.
 96. Hunter AL, Bai N, McManus BM, Laher I, Granville DJ. (2005). Sulfaphenazole reduces superoxide generation and improves vascular function following ischemia and reperfusion. *Experimental Biology 2005 meeting in San Diego, CA, April 4, 2005. The FASEB Journal*. 19(4): A485.
 97. Hunter AL Bai N, McManus BM, Laher I, Granville DJ. (2005) Cytochrome p450 enzymes contribute to superoxide production and vascular dysfunction following ischemia and reperfusion. The 2nd Annual National Research Forum for Young Investigators in Cardiovascular and Respiratory Health, Winnipeg, MB. *Exp Clin Cardiol*. 10:1, 31.
 98. Bai N, Khazaei M, Laher I, Van Eeden SF (2005). Particulate matter reduces vascular endothelial function. 12th World Congress on Heart Disease. Vancouver, BC, Canada, July 2005
 99. Khazaei M, Moien-Afshari F, Laher I (2005) Lifestyle modifications improve vascular dysfunction in type 2 diabetes. 17th Iranian Congress of Physiology and Pharmacology. Kerman, Iran, October, 2005
 100. Moien-Afshari F, Laher I (2005) Towards an improved understanding of transplant vascular disease. 17th Iranian Congress of Physiology and Pharmacology. Kerman, Iran, October, 2005
 101. Bai N, Laher I, Baker C, Rosenfeld ME, and van Eeden SF (2006). Acute diesel exhaust particle exposure induces vasoconstriction in Apoe deficiency mice. American Thoracic Society International Conference, San Diego, CA, USA. May 2006.
 102. Bai N, Suzuki H, Corey LM, Kido T, Rosenfeld ME, Laher I and van Eeden S (2007). Mechanisms of chronic diesel exhaust particle inhalation- induced

- exaggerated vasoconstriction in mouse aorta. American Thoracic Society International Conference, San Francisco, CA, USA, May 2007.
103. Rahman MM, Elmi S, Chang TKH, Bai N, Sallam NA, Lemos VS, Moien-Afshari F, Laher I (2007). Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release. The 71st Annual Meeting of the Japanese Circulation Society, Kobe, Japan, March 2007.
 104. Bai N, Suzuki H, Corey Lm, Kido T, Rosenfeld Me, Laher I, Van Eeden SF (2007) Chronic diesel exhaust particle inhalation induces exaggerated vasocontraction in Apo-E knockout mouse aorta. The 13th World Congress on Heart Failure, Vancouver, Canada. July 2007
 105. Rahman MM, Elmi S, Chang T, Bai, Sallam N, Lemos V, Moien-Afshari F, Laher I. (2007) Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release. Presented at Life Sciences 2007. A joint meeting of the Biochemical Society, the British Pharmacological Society and the Physiological Society. Glasgow, Scotland. July, 2007.
 106. Rahman MM, Elmi S, Chang T, Bai, Sallam N, Lemos V, Moien-Afshari F, Laher I. (2007) Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release. Presented at the 13th World Congress on Heart Disease, International Academy of Cardiology Annual Meeting held in Vancouver, Canada. July, 2007.
 107. Khazaei M, Moien-Afshari F, Laher I. (2007) Exercise improves vascular endothelial function in type-II diabetic mice. Presented at the 18th Iranian Congress of Physiology & Pharmacology. Mashhad, Iran. August, 2007.
 108. Khazaei M, Moien-Afshari F, Elmi SH, Rahman MM, Sallam N, Laher I. (2007) Low and moderate intensity exercise reverse diabetic endothelial dysfunction by increasing the expression of different subtypes of SOD. Presented at the 18th Iranian Congress of Physiology & Pharmacology. Mashhad, Iran. August 2007.
 109. Khazaei M, Moien-Afshari F, Rahman MM, Ghosh S, Rodrigues B, McNiell JH, Laher I (2007). Exercised-induced improvement in endothelial function in db/db type II diabetic mice occurs independently of weight loss. Presented at the 18th Iranian Congress of Physiology & Pharmacology. Mashhad, Iran August 2007.
 110. Ghosh S, Moien-Afshari F, Khazaei M, Laher I (2008). Exercise improves coronary artery function in diabetic mice. Submitted for presentation to 9th International Symposia on Resistance Arteries 2008 (Hamilton Island, Australia) February 2008.
 111. Liang W, Tan CYR, Wright JM, Laher I (2008) Ramipril treatment improves vascular endothelial function in db/db mice. Presented at the Experimental Biology Meeting San Diego, California, USA. April 2008.
 112. Bai N, Kido T, Corey LM, Laher I, Rosenfeld M, van Eeden S (2008) Effect of chronic diesel exhaust particle inhalation on endothelial function of mouse aorta. Presented at the International Conference of the American Thoracic Society in Toronto, Canada. May 2008.
 113. Ghosh S, Moien-Afshari F, Khazai M, Verchere B, Laher I (2008) Exercise restores coronary vascular function independent of myogenic tone or hypoglycemic status in db/db mice. Presented at the Canadian Cardiovascular Congress Toronto, Canada. October 2008.

114. Vadhavkar M, Laher I, Stothers L (2009) Exercise improves bladder function of diabetic mice. Presented at Northwest Urological Society 56th Annual Conference held in Bellevue, Washington, USA. December 2009.
115. Ramer LM, Alan N, Inskip JA, Golbidi S, Ramer MS, Laher I, Krassioukov AV (2009). Impaired local vasodilation may contribute to cardiovascular dysfunction following spinal cord injury. Presented at Congress on Spinal Cord Medicine and Rehabilitation. Dallas, Texas, USA. September 2009.
116. Ramer LM, Alan N, Inskip JA, Golbidi S, Ramer MS, Laher I, Krassioukov AV (2009). Impaired local vasodilation may contribute to cardiovascular dysfunction following spinal cord injury. Presented at the Thirteenth International Symposium on Neural Regeneration. Pacific Grove, California, USA. December 2009.
117. War SA, Foot ES, Somvanshi RK, Chaudhari N, Kharmate G, Rajput PS, Qui X, laher I, Kumar U (2010). Somatostatin receptor specific changes in the brain regions of db/db mouse model of type 2 diabetes. Presented at the Annual Meeting of the Endocrinology Society (San Diego, California, USA; June 2010).
118. Laher I (2010). Exercise in type 2 diabetes: some mechanistic insights. Presented at 16th World Congress of Basic and Clinical Pharmacology (IUPHAR—WorldPharma 2010) (Copenhagen, Denmark; July 2010).
119. Halder S, Laher I, Golbidi S, Beam J, Bahniwal R, Ghosh S (2011). Exercise aggravates cardiac oxidative stress, apoptosis and fibrosis in aged db/db mice. Presented at the Annual Canadian Diabetes Association Meeting (Toronto, Canada, September 2011).
120. Aleliunas RE, Olson JD, Aljaadi AM, Glier MB, Laher I, Green TJ, Devlin AM (2012). Programming of adiposity by prenatal exposure to maternal folic acid and vitamin B12 imbalance. Presented at the Canadian Cardiovascular Congress (Toronto, Canada, October 2012).
121. Badran M, Laher I, Golbidi S, Ayas, N (2013). Chronic intermittent hypoxia induces endothelial dysfunction in mice fed a high fat diet but not in mice fed a normal diet. Presented at Experimental Biology 2013 (Boston, USA, April 2013).
122. Aleliunas RE, Golbidi S, Olson JD, Glier MB, Laher I, Green T, Devlin AM (2014). Developmental exposure to maternal folic acid intake programs vascular NADPH oxidase expression in mice. Presented at Experimental Biology 2014 (San Diego, USA, April 2014).
123. Sallam N, Wang B, Laher I (2014) Exercise training and vascular reactivity in db/db mice: mechanisms beyond weight loss. Submitted for presentation to International Union of Basic and Clinical Pharmacology (IUPHAR). 17th World Congress of Basic & Clinical Pharmacology (Cape Town, South Africa, July 2014)
124. Ghosh S, Botta A, Gottfred S, Laher I (2014). Myocardial GSH determines the mode of cell death following exercise in aging diabetic hearts in vivo. Submitted for presentation to International Union of Basic and Clinical Pharmacology (IUPHAR). 17th World Congress of Basic & Clinical Pharmacology (Cape Town, South Africa, July 2014)
- 125.

3. BOOKS

Book Chapters

1. Bevan JA, Hwa JJ, Laher I, Owen MP (1985): Calcium, dihydropyridines and resistance vessel tone. In *Bayer Symposium IX, Cardiovascular Effects of Dihydropyridine-type Calcium Antagonists and Agonists*, edited by Fleckenstein A, Van Breemen C. Berlin, Springer Verlag, pp. 362-367.
2. Laher I, Bevan JA (1988): Stretch-dependent calcium entry in vascular smooth muscle. In *Vascular Neuroeffector Mechanisms*. Proc. Sixth Int. Symposium, Ed. Bevan JA, Majewski H, Maxwell RA, Story DF, pp. 225-231.
3. Laher I, van Breemen C (1971): Regulation of calcium sensitivity in vascular smooth muscle. In *The Resistance Vasculature*, edited by Bevan JA, Halpern W, Mulvany MJ, Humana Press, New Jersey, pp. 305-317.
4. Laher I, Bevan JA (1993): Stretch-dependent myogenic tone in isolated blood vessels. In *Mechanoreception by the Vascular Wall*, Edited by Rubanyi GM, Futura Co., N.Y., pp 13-36.
5. Laher I, Bevan JA (1994): Receptor synergism in cerebral arteries; role of protein kinase C. In *The Human Brain Circulation*, edited by Bevan JA, Bevan RD, Humana Press, New Jersey, pp. 389-397.
6. Laher I, Germann P, Bevan JA (1993): Protein kinase C modulates increased cerebrovascular reactivity caused by activated platelets. In *Proceedings of the Vth International Conference on Cerebral Vasospasm*, edited by Findlay JM, Elsevier Science Publishers, Amsterdam. Develop. Neurol. 8:117-120.
7. Laporte R, Laher I: The sarcoplasmic reticulum as a modulator of vascular tone. In *The Resistance Arteries*, Edited by Halpern W, Bevan JA, Brayden J, Dustan H, Nelson M, Osol G, Humana Press, Totowa, NJ, pp. 61-70, 1994.
8. Chen Q, Laher I, van Breemen C (1995): Integration of plasmalemmal and sarcoplasmic reticular Ca²⁺-transport in smooth muscle. In *Pharmacological Control of Calcium and Potassium Homeostasis*, Ed. Paoletti R, Vahoutte PM, GodfraindT, Kluwer Academics Publishers, Dordrecht, The Netherlands, pp 9-16.
9. Wang X, Laher I, van Breemen C (1996): Ca²⁺ signalling in the vascular wall: smooth muscle and endothelium. In *International Nimodipine Symposium*, Ed. Saida K, Excerpta Medica Ltd., Tokyo, Japan, pp 3-15,.
10. LagaudGL, Skarsgard P, Laher I, van Breemen C (1999): Heterogeneity and plasticity of autocoid release by endothelium of resistance arteries of the rat. In *EDHF: Second International Meeting*. Ed. Vanhoutte P, Harwood Academic Press, Reading, UK. pp 265-278.
11. Yanagawa B, Esfandiarei M, Carthy C, Cheung P, Luo H, Granville D, Yang DC, Choy J, Lui A, Dabiri D, Wilson JE, Wang A, Zhang M, Sinn S, McManus BM, Wei K, Laher I (2003): Life and Death Signaling Pathways in CVB3-Induced Myocarditis In *Myocarditis: Bench to the Bedside*. Ed. Cooper L. Humana Press, Totowa, New Jersey. pp 161-195.

12. Kuang X, Chan L, Liang W, Laher I, van Breemen C, Wang X (2003). The Role Of K_{ca} In Endothelial Cell Hyperpolarization And Endothelium-Dependent Relaxation In the Rabbit Aorta. In *EDHF: Third International Meeting*. Ed. Vanhoutte P, Harwood Academic Press, Reading, UK pp 274-282.
13. Moien-Afshari F, Choy JC, McManus BM, Laher I (2007). Immunosuppression in promotion of cardiac allograft vasculopathy. In: *Immune dysfunction and immunotherapy in heart disease*. Ed. RR Watson and D. Larson, Blackwell Publishers, Massachusetts, USA pp57-79.
14. Bai N, Laher I, van Eeden, S (2007). Systemic response to ambient particulate matter air pollution and the implications for cardiovascular disease. In *Air Pollution Research Trends*. Ed. Sergio F. Balduino. Nova Science Publishers, New York pp 43-74.
15. Golbidi S, Leung FP, Tsang FSY, Huang Y, Laher I (2010). An overview of postmenopausal care: cardiovascular aspects. In *Menopause: Vasomotor Symptoms, Systemic Treatments and Self-Care Measures*. Ed. J Michalski and I. Nowak, Nova Science Publishers, New York, 2010 pp 55-95.
16. Laher I, Zhang X, Leung PC, Liang W (2014). Diverse pharmacological properties of ketamine. In *Ketamine: Use and Abuse*. Edited by David T. Yew, Taylor and Francis. (In Press)